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 Sparstolonin B (SsnB) is a novel bioreactive compound isolated from Sparganium 
stoloniferum, an herb historically used in Traditional Chinese M dicine as an anti-tumor 
agent.  SsnB has demonstrated anti-inflammatory properties, inhibiting Toll-like receptor 
mediated inflammation in isolated macrophages and in mice.  Angiogenesis, the process 
of new capillary formation from existing blood vessls, is dysregulated in many 
pathological disorders, including atherosclerosis, diabetic retinopathy, and tumor growth.  
The goal of the project was to investigate the anti- giogenic effects of SsnB. 
 The first part of the project utilized in vitro functional assays to study how SsnB 
affected endothelial cells.  SsnB inhibited endothelial cell tube formation (Matrigel 
method) and cell migration (Transwell method) in a dose-dependent manner.  Microarray 
experiments with human umbilical vein endothelial cel s (HUVECs) and human coronary 
artery endothelial cells (HCAECs) demonstrated differential expression of several 
hundred genes in response to SsnB exposure (916  and 356 genes, respectively, with fold 
change ≥ 2, p < 0.05, unpaired t-test).  Microarray data from both cell types showed 
significant overlap, including genes associated with cell proliferation and cell cycle.  
Flow cytometric cell cycle analysis of HUVECs treatd with SsnB showed an increase of 
cells in the G1 phase and a decrease of cells in the S phase.  Cyclin E2 (CCNE2) and Cell 
division cycle 6 (CDC6) are regulatory proteins that control cell cycle progression 
through the G1/S checkpoint.  Both CCNE2 and CDC6 were downregulated in the 
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microarray data.  Real Time quantitative PCR confirmed that gene expression of CCNE2 
and CDC6 in HUVECs was downregulated after SsnB exposure, to 64% and 35% of 
controls, respectively.  The data suggest that SsnB may exert its anti-angiogenic 
properties by downregulating CCNE2 and CDC6, halting progression through the G1/S 
checkpoint. 
 In the second portion of the project, a chick chorioallantoic membrane (CAM) 
assay was utilized to investigate SsnB inhibition of ex vivo angiogenesis. Chick embryos 
were exposed to methylcelluose discs containing vehicle control (DMSO) or SsnB.  
Chick embryos receiving SsnB discs showed significant reduction in capillary length and 
branching relative to the vehicle control group.  Overall, SsnB caused a significant 
reduction in angiogenesis, demonstrating its ex vivo efficacy.
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 Atherosclerosis is a serious chronic disease affecting a significant portion of the 
U.S. population and causing many deaths, from conditi s such as ischemic stroke and 
myocardial infarction.  There are many risk factors f r atherosclerosis including 
hypertension, smoking, diabetes, high-fat diet, and dyslipidemia.  Atherosclerosis 
specifically involves the formation of plaques within blood vessels, progressing through 
several stages (illustrated in Figure 1.1).  In the earliest stage, fatty streaks or atheromas 
form as lipids and lipoproteins deposit in the tunica intima of the blood vessel.  A high 
ratio of LDL:HDL favors this event.  The lipid deposits become oxidized and induce 
injury to the endothelial cells lining the blood vess l.  Endothelial injury is a key step in 
atherosclerosis; endothelial cells may also be injured by denuding events or by more 
subtle hemodynamic changes.  Cell adhesion molecules are upregulated in the 
endothelium, and inflammatory cells are attracted to the site of injury, including 
monocytes which differentiate into macrophages.  As macrophages migrate to the area of 
oxidized lipids, scavenger receptors and toll-like receptors bind the lipids and help 
activate the macrophages to release inflammatory cytokines and mediators.  The 
macrophages transform into foam cells as they take up oxidized lipids.  Additional cells 
migrate to the area, including mast cells and leukocytes.  An advanced lesion forms as 
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smooth muscle cells from the tunica media proliferate, migrate into the plaque, and form 
a fibrous cap.  The smooth muscle cells may also transform into foam cells.  An area of 
dead cells and cholesterol crystals forms within the plaque.  A capillary network also 
grows within the plaque to help provide nutrients, gases, and inflammatory cells to the 
growing plaque.  Blood vessels within the tunica adventitia, known as the vasa vasorum, 
supply this capillary network.  As the plaque progresses, the fibrous cap weakens and 
ruptures, exposing the highly thrombogenic necrotic core region.  Thrombus formation 
subsequently ensues.  The thrombus may occlude the vess l or become an embolus that 
travels to another region of the body (Sluimer and Daemen 2009). 
 
Figure 1.1  Atherosclerotic Plaque Progression. 
 Plaque formation does not typically occur in wild type mice.  However, ApoE 
knockout mice and LDL receptor knockout mice show significant plaque progression 
after several months on a high fat diet (such as the Western Diet).  Plaque formation in 
mice can be accelerated by surgical interventions which alter hemodynamics or induce 
endothelial injury. These procedures include complete and partial carotid ligation, where 
the entire common carotid artery or its branches ar ligated with sutures.  The resulting 
decreased blood flow and oscillatory shear stress rduce the time to plaque formation.  
Another model of atherosclerosis in mice is wire-induced endothelial cell injury.  In this 
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model, a wire is inserted into the carotid artery, and the luminal surface is scraped to 
induce endothelial injury.  A similar model involves the application of electrical current 
to the carotid.  Mice may also be injected with lipopolysaccharide, derived from gram 
negative bacteria, to induce an inflammatory respone and cause atherosclerosis (Nam et 
al. 2009). 
Intraplaque Angiogenesis 
 Atherosclerotic plaque rupture is the leading cause of acute cardiovascular events 
such as myocardial infarction (“heart attack”) and ischemic stroke. In this process, the 
fibrous cap overlying an atherosclerotic plaque fails, resulting in rapid thrombus 
formation which may completely occlude the vessel, leading to ischemia and tissue death 
downstream of the blockage.  Newly developed and recur ing myocardial infarction 
afflicts approximately 1.1 million people in the USA per year, with a 40% fatality rate; 
220,000 of these deaths occur without hospitalization.  Roughly 75% of these clinical 
events are caused by atherosclerotic plaque rupture. Clearly, methods of stabilizing 
atherosclerotic plaques to prevent plaque rupture would have a significant clinical impact 
(Sluimer and Daemen 2009). 
 Research has shown a link between capillary networks within atherosclerotic 
plaques and plaque progression and rupture (Sluimer et al. 2009).   Under normal 
physiological conditions, only thick-walled blood vessels such as the descending aorta 
and the common carotid artery contain an intramural capillary network.  This network of 
blood vessels, known as the vasa vasorum, is situated in the tunica adventitia and outer 
third of the tunica media.  It supplies the blood vessel wall with nutrients and allows gas 
4 
exchange.  Human atherosclerotic arteries have shown extensive intraplaque 
angiogenesis, often linked to the vasa vasorum.  It has been suggested that hypoxia and/or 
reactive oxygen species are responsible for initiating new capillary formation (Khurana et 
al. 2005).   Capillary networks within atherosclerotic plaques serve as a source of 
inflammatory cells, nutrients, and mediators, allowing the neo-intima to expand beyond 
the normal wall thickness.  Intraplaque angiogenesis is correlated with decreased plaque 
stability and increased incidence of plaque rupture, subsequent thrombus formation, and 
intra-arterial occlusion.  Recent research has suggested that inhibiting angiogenesis may 
improve plaque stability and decrease the chances for plaque rupture (Moreno et al. 2004; 
Virmani et al. 2005).  In addition, inhibiting angio enesis may decrease plaque formation 
by limiting this supply of necessary factors to theplaque region (Sluimer and Daemen 
2009). 
Oxidative stress and reactive oxygen species (ROS) have been linked to many 
different pathological states, including atherosclerosis.  ROS are also employed in normal 
physiological responses in vascular cells, including intracellular signaling.  ROS include 
hydrogen peroxide, superoxide anion, nitric oxide (NO), peroxynitrite, and hydroxyl 
radical.  Sources of ROS include NADPH oxidases, eNOS, lipoxygenases, the 
mitochondrial electron chain, and xanthine oxidase.  R active oxygen species can also be 
found in environmental sources, such as cigarette smoke and diesel exhaust fumes.  
Certain reactive oxygen species, such as the superoxid  anion, may react with NO, 
forming peroxynitrite which oxidizes and damages lipid membranes, lipoproteins, and 
cellular enzymes.  As NO becomes inactivated, vasodilation is impaired, resulting in a 
state of hypertension.  ROS may also increase cell adhesion molecules in endothelial 
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cells, leading to a state of vascular inflammation.  All of the preceding effects predispose 
the vasculature to atherosclerosis (Ushio-Fukai et l. 1999). 
Steps Involved in Angiogenesis 
 Angiogenesis is one mechanism of new blood vessel formation.  Specifically, 
angiogenesis refers to capillary formation from existing blood vessels; whereas, 
vasculogenesis refers to the d novo formation of blood vessels during embryogenesis.  
Angiogenesis plays an important role in many normal events in the body, including 
wound healing, embryogenesis, and female reproductive processes.  During these normal 
processes, angiogenesis is highly regulated.  Unregulated angiogenesis contributes to 
many pathological conditions, such as rheumatoid arthritis, psoriasis, retinopathy, and 
tumor growth and metastasis.  Clearly, angiogenesis is an important event in the human 
body.  In addition, endothelial cells play a key role during angiogenesis.  Therefore, an 
understanding of endothelial cell functions is essential when discussing angiogenesis 
(Bussolino, Mantovani, and Persico 1997). 
Angiogenesis is a complex event that occurs in several stages and involves 
interactions between cells, soluble factors, and extracellular matrix molecules.  First, 
proteolytic enzymes break down the basement membrane of an existing blood vessel.  
Endothelial cells with the help of proteolytic enzymes, including matrix 
metalloproteinases (MMPs) and the plasminogen activtor system (PA), break down the 
basement membrane and invade the surrounding tissues.  The PA system is comprised of 
the serine proteases urokinase-type plasminogen activator (uPA) and tissue-type 
plasminogen activator (tPA) that convert plasminogen into its active form, plasmin.  
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Plasmin degrades numerous extracellular matrix proteins, including fibronectin, laminin, 
and fibrin.  Plasmin also helps activate many MMPs.  Matrix metalloproteinases are more 
specific in the matrix molecules that they degrade.  After the basement membrane of the 
blood vessel is broken down, endothelial cells migrate into the surrounding tissue and 
proliferate.  Growth factors and other soluble proteins in the ECM often facilitate and 
regulate this process.  The growth factors that are stored bound to the ECM can be 
released as the ECM is degraded by proteases.  Certain g owth factors, such as vascular 
endothelial growth factor, act as chemoattractants that facilitate the migration of 
endothelial cells to certain locations.  After proliferation and migration, the endothelial 
cells form a new lumen and start to secrete extracellular matrix molecules, ultimately 
forming a new capillary (Liekens, De Clercq, and Neyts 2001). 
Preliminary Research 
 The strong connection between plaque instability and ngiogenesis initially 
captured our attention.  What causes intraplaque angiogenesis?  How can we inhibit 
intraplaque angiogenesis?  Will inhibiting angiogenesis prevent plaque rupture?  These 
were questions that first intrigued us.  Our preliminary research sought to investigate the 
cause and process of angiogenesis within atheroscleti  plaques.  We hypothesized that 
reactive oxygen species were responsible for capillary formation within plaques.  Later 
we decided to investigate the anti-angiogenic properties of the plant derived compound 
Sparstolonin B.  We will first begin with a brief description of the preliminary research 
conducted on reactive oxygen species and intraplaque ngiogenesis.  The majority of this 
dissertation will then be devoted to examining Sparstolonin B and its anti-angiogenic 
properties. 
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 To study the relationship between reactive oxygen species, angiogenesis, and 
atherosclerosis, a mouse model of atherosclerosis was utilized.  In this model, ApoE 
knockout mice underwent left carotid ligation.  The ligated mice were placed on a high 
cholesterol diet (Paigen Diet - 1.25% cholesterol) for 0, 7, 14, and 21 days.  During this 
time, atherosclerotic plaques developed within each ligated carotid artery.  After the 
appropriate time course, the mice were sacrificed and perfused with heparinized saline 
and neutral buffered formalin.  Both left and right carotid arteries were dissected in an 
entire block, including the trachea and esophagus.  Carotid blocks were fixed, processed, 
and embedded in paraffin.  The specimens were section d into 5 um sections and 
collected on glass slides.  Plaque formation was demonstrated by hematoxylin and eosin 
(H&E) and Masson’s Trichrome staining.  To investiga e reactive oxygen species 
formation in the plaque, antibodies against 8-isoprostane (8-IP) were chosen.  8-IP forms 
after reactive oxygen species react with components of the cell membrane.  The slides 
were deparaffinized and hydrated; immunohistochemical staining was performed to 
detect 8-IP.  A colorimetric reaction was utilized to detect the presence of 8-IP.  Light 
microscopic images were acquired with a 10X objectiv  lens, and the stained area within 
sections was measured with Image-Pro Plus image analysis software. 
 Immunohistochemical staining for 8-IP was performed on carotid artery sections 
taken from mice that had undergone a complete carotid artery ligation for 0, 7, 14, or 21 
days.  The staining results were analyzed by dividing each carotid image into three 
separate regions (intima, media, and adventitia) and measuring the positively stained area 
in each region (see Appendix, Figure A.1).  The media region exhibited the least amount 
of staining in all sections; whereas, the adventitia exhibited the most staining.  Day 14 
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specimens demonstrated the largest stained area, and Day 0 showed the least staining.  
Overall, 8-IP seemed to increase over time and peakon Day 14.  Afterwards, 8-IP 
staining dropped on Day 21.  In addition, Day 14 and 21 sections showed areas of 8-IP 
staining that overlapped with capillary networks identified by antibody Ter 119 
(erythroid cell marker) and hematoxylin and eosin stains.  Day 7, 14, and 21 sections 
exhibited 8-IP staining in areas containing foam cells and adventitial fat cells.  Day 0 
staining was confined to the endothelium.  These reults suggest that ROS formation 
increases during atherosclerotic plaque development in this mouse model. 
 The results demonstrated a potential role for reactive oxygen species in capillary 
formation within atherosclerotic plaques.  8-isoprostane is formed when reactive oxygen 
species react with arachidonic acid, a component of cellular membranes.  Since 8-IP is 
elevated in the neointima at 14 and 21 days after carotid ligation, this implies that 
reactive oxygen species are present in the atheroscl ti  plaques.  The colocalization of 
8-IP and intraplaque capillary networks suggests that ROS may be involved in 
neovascularization.  Day 14 sections demonstrate 8-IP staining before intraplaque vessels 
are present, supporting this hypothesis.  Hypoxia has been show to be a major driving 
force for angiogenesis, but other factors, such as re ctive oxygen species, may play a key 
role in this process.  ROS may activate many of the same angiogenic pathways as 
hypoxia, including the stabilization of the transcription factor hypoxia inducible factor 
(HIF)-1α which upregulates VEGF.  Future directions could incorporate research into the 




Angiogenesis Inhibition and Sparstolonin B 
 The research outlined above explored a potential stimulus for intraplaque 
angiogenesis.  After completing this research, it was deemed important to investigate new 
ways to inhibit angiogenesis.  New methods to inhibit angiogenesis may hold the key to 
new treatments not only for atherosclerosis, but also for various other angiogenesis-
related pathological conditions, including psoriasis, cancer, and rheumatoid arthritis.  
Sparstolonin B (SsnB) is a newly isolated compound from the aquatic herb, Sparganium 
stoloniferum.  Based on prior research conducted on both SsnB and the parent plant 
(described in the following pages), we hypothesized that SsnB would inhibit 
angiogenesis. 
 Angiogenesis may be inhibited at multiple steps.  Growth factors, including 
Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF), 
are suitable targets.  Current approaches to sequester VEGF include soluble VEGF 
receptors and neutralizing antibodies against VEGF.  Intracellular signaling molecules, 
including tyrosine kinases, can be inhibited to prevent receptor-mediated activation of 
endothelial cells.  There also exist natural angiogenesis inhibitors, including endostatin, 
retinoids, and fibronectin fragment, which may be targeted for angiogenesis inhibition.  
Angiogenesis inhibitors often target endothelial cells through the inhibition of cell 
proliferation, migration, and protease production.  Current research into angiogenesis 
inhibition has demonstrated ways to limit atherosclerosis.  By inhibiting intraplaque 
angiogenesis, necessary factors, such as inflammatory cells, oxygen, and mediators, are 
not delivered to the growing plaque, diminishing plaque growth.  Plaque stability may 
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also be improved, decreasing the likelihood of plaque rupture and subsequent thrombosis 
and stroke or myocardial infarction (Pandya, Dhalla, and Santani 2006). 
 Sparstolonin B (SsnB) is a novel bioactive compound isolated from the plant 
Sparganium stoloniferum by Dr. Qiaoli Liang from the laboratory of Dr. Daping Fan at 
the University of South Carolina School of Medicine (Liang et al. 2011).  Sparganium 
stoloniferum is a perennial, aquatic plant grown in North and East China, whose tubers 
have long been used in Traditional Chinese Medicine (TCM) for the treatment of several 
inflammatory diseases and as an anti-spasmodic and anti-tumor agent.  Previous work 
with this herb has mainly dealt with its extracts.   SsnB is one of several chemical 
compounds that have been isolated and characterized f om Sparganium stoloniferum.  
NMR and X-ray crystallography have identified SsnB as a polyphenol with structural 
similarities to isocoumarins and xanthone (see Figure 1.2).  Isocoumarins are a class of 
compounds that often exhibit anti-coagulant, anti-iflammatory, and anti-tumor 





         Figure 1.2  Structure of SsnB 
 SsnB shows potential as a safe, non-toxic pharmaceutical agent for the treatment 
of several pathological conditions.  At concentrations up to 100 µM, SsnB does not 
exhibit cytotoxic effects on various cell types, including peritoneal mouse macrophages, 
phorbol myristate acetate (PMA)-differentiated THP-1 macrophages, Human Umbilical 
Vein Endothelial Cells (HUVECs), Human Aortic Smooth Muscle Cells (HASMCs), and 
monocytic THP-1 cells.  Prior research has shown that SsnB exhibits strong anti-
inflammatory effects on mouse and human macrophages, selectively inhibiting the 
inflammatory responses of macrophages to ligands for Toll-like Receptors 2 and 4 (TLR2 
and TLR4).  SsnB has also been shown to suppress downstream signaling pathways after 
TLR2 and TLR4 activation, including MAPK and NF-κB.  These findings suggest that 
SsnB may be an antagonist to TLR2 and TLR4 (Liang et al. 2011). 
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 Targeting endothelial cell proliferation has shown potential in the area of 
angiogenesis inhibition.  Endothelial cell proliferation may be inhibited in numerous 
ways, including the downregulation of cell cycle regulatory proteins (Pandya, Dhalla, and 
Santani 2006).  Cyclins and cyclin dependent kinases r  regulatory proteins that control 
progression through the cell cycle by regulating specific cell cycle checkpoints.  Cyclins 
help activate cyclin dependent kinases, which phosprylate downstream proteins that 
allow cells to progress through these checkpoints.  Cyclin E2 (CCNE2) and Cell Division 
Cycle 6 (CDC6) are regulatory proteins that control pr gression through the G1 
checkpoint (see Figure 1.3).  Downregulation of CCNE2 and CDC6 could trap cells at the 
G1 checkpoint and prevent endothelial cells from enteri g the final stages of cell division 
(Wu et al. 2009; Borlado and Mendez 2008).  We have hypothesized that SsnB may exert 
anti-angiogenic effects by downregulating CCNE2 andCDC6, trapping endothelial cells 
at the G1 checkpoint and preventing complete cell division. 
 
      Figure 1.3  Cell Cycle 
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 The parent plant Sparganium stoloniferum has been used for centuries in 
Traditional Chinese Medicine for the treatment of can er.  Furthermore, previously 
published research has shown that extracts and other isolated chemical compounds from 
this herb, including a sucrose ester, a phenylpropan id glycerol, carboxylic acid esters, 
and a phenylpropanoid glycoside, have demonstrated potent anti-cancer effects (Li et al.).  
Compounds used to treat tumors often possess the ability to inhibit angiogenesis, among 
other properties.  This enables these compounds to limi  blood vessel growth into 
growing tumors, limiting the supply of necessary nutrients and cells and subsequently 
inhibiting tumor growth (Meng et al.).  Since SsnB is derived from this plant used in 
cancer treatment, we tested the hypothesis that SsnB may possess anti-angiogenic 
properties in addition to its already established anti-inflammatory properties.  Moreover, 
SsnB offers advantages over current protein angiogenesis inhibitors, including angiostatin 
and thrombospondin, which require parenteral administration. 
Specific Aims  
 The overall goal of the project is to demonstrate that SsnB inhibits angiogenesis 
and to determine its mechanism of action in blocking a giogenesis.  Our initial in vitro 
studies demonstrated the potential of SsnB as an anti-angiogenic agent, which inhibits 
human endothelial cell tube formation and migration.  Our microarray data showed how 
SsnB affected gene expression, with an enrichment of differentially regulated genes 
associated with cell proliferation, replication, migration, and cell cycle.  SsnB arrested 
endothelial cell division in the G1 phase in association with downregulating the cell cycle 
proteins cdc6 and cyclin E2.  Furthermore, we demonstrated that SsnB inhibited ex vivo 
angiogenesis in the chick chorioallantoic membrane ssay.  Overall, we hypothesize that 
14 
SsnB inhibits angiogenesis by targeting endothelial cell cycle progression, cell migration, 
and chemotaxis.  The project may ultimately demonstrate the potential of SsnB as a 
pharmaceutical compound used to inhibit angiogenesis and possibly to stabilize 
atherosclerotic plaques.    
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Specific Aim 1 – Functional Assays: 
To demonstrate the anti-angiogenic effects of SsnB through in vitro functional assays 
using human endothelial cells. 
Specific Aim 2 – Mechanistic Studies: 
A.   Microarray: 
 To test the effects of SsnB on the gene expression pr file of Human Umbilical 
 Vein Endothelial Cells (HUVECs) and Human Coronary A tery Endothelial Cells 
 (HCAECs). 
 B.   Cell Cycle Regulation: 
 To investigate how SsnB affects expression of genes for cell cycle regulatory 
 proteins and progression through the cell cycle. 
Specific Aim 3 – Ex vivo Studies: 
To demonstrate the anti-angiogenic effects of SsnB in the ex vivo chick chorioallantoic 
membrane (CAM) assay. 
 Specific Aim 1 involved the use of several in vitro functional assays to reveal if 
and how SsnB inhibited angiogenesis-related functios n isolated endothelial cells.  
Specific Aim 2 further investigated the mechanism of inhibition by examining changes in 
gene expression with microarrays and determining how SsnB affected cell cycle 
progression.  Specific Aim 3 demonstrated angiogenesis inhibition in an ex vivo system.  
Overall, SsnB exhibits many diverse effects, including anti-inflammatory, anti-
16 
angiogenic, and cytostatic properties, which suggest that it may have potential therapeutic 





SPARSTOLONIN B INHIBITS PRO-ANGIOGENIC FUNCTIONS AND BLOCKS CELL CYCLE 
PROGRESSION IN ENDOTHELIAL CELLS 
 
Abstract 
 Sparstolonin B (SsnB) is a novel bioactive compound isolated from Sparganium 
stoloniferum, an herb historically used in Traditional Chinese M dicine as an anti-tumor 
agent.  Angiogenesis, the process of new capillary formation from existing blood vessels, 
is dysregulated in many pathological disorders, including diabetic retinopathy, tumor 
growth, and atherosclerosis.  In functional assays, SsnB inhibited endothelial cell tube 
formation (Matrigel method) and cell migration (Transwell method) in a dose-dependent 
manner.  Microarray experiments with human umbilical vein endothelial cells (HUVECs) 
and human coronary artery endothelial cells (HCAECs) demonstrated differential 
expression of several hundred genes in response to SsnB exposure (916  and 356 genes, 
respectively, with fold change ≥ 2, p < 0.05, unpaired t-test).  Microarray data from both 
cell types showed significant overlap, including genes associated with cell proliferation 
and cell cycle.  Flow cytometric cell cycle analysis of HUVECs treated with SsnB 
showed an increase of cells in the G1 phase and a decrease of cells in the S phase.  Cyclin 
E2 (CCNE2) and Cell division cycle 6 (CDC6) are regulatory proteins that control cell 
cycle progression through the G1/S checkpoint.  Both CCNE2 and CDC6 were 
downregulated in the microarray data.  Real Time quantitative PCR confirmed that gene 
expression of CCNE2 and CDC6 in HUVECs was downregulated after SsnB exposure, to
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 64% and 35% of controls, respectively.  The data suggest that SsnB may exert its anti-
angiogenic properties in part by downregulating CCNE2 and CDC6, halting progression 
through the G1/S checkpoint.   
Introduction 
 Sparstolonin B (SsnB) is a novel bioactive compound isolated from the plant 
Sparganium stoloniferum, a perennial, aquatic plant grown in North and East China, 
whose tubers have long been used in Traditional Chinese Medicine (TCM) for the 
treatment of several inflammatory diseases and as an nti-spasmodic and anti-tumor 
agent.  NMR and X-ray crystallography have identified SsnB as a polyphenol with 
structural similarities to isocoumarins, a class of compounds that often exhibit anti-
coagulant, anti-inflammatory, and anti-tumor properties (Qiu 2008; Xiong et al. 2009; 
Liang et al. 2011).  SsnB may hold potential as a safe, non-toxic pharmaceutical agent for 
the treatment of several pathological conditions.  At concentrations up to 100 µM, SsnB 
does not exhibit cytotoxic effects on various cell types, including mouse peritoneal 
macrophages, HUVECs, human aortic smooth muscle cells, and monocytic THP-1 cells.  
Prior research has shown that SsnB exhibits strong anti-inflammatory effects on mouse 
and human macrophages by selectively inhibiting the inflammatory responses of 
macrophages to ligands for Toll-like Receptor (TLR) 2 and TLR4.  SsnB has also been 
shown to suppress downstream signaling pathways after TLR2 and TLR4 activation, 
including MAPK and NF-κB (Liang et al. 2011).  These findings suggest that SsnB may 
be an antagonist to TLR2 and TLR4. 
 Angiogenesis refers to capillary formation from existing blood vessels.  
Angiogenesis plays an important role in many physiological events in the body, including 
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wound healing, embryogenesis, and female reproductive processes (Folkman 1971; Risau 
1997).  During these normal processes, angiogenesis is h ghly regulated.  Unregulated, 
excessive angiogenesis contributes to many pathologies, such as rheumatoid arthritis, 
psoriasis, retinopathy, and tumor growth and metastasis (Staton, Reed, and Brown 2009).  
Inhibiting pathological angiogenesis may prove to be an effective therapy for these 
angiogenesis-related diseases.   
 Angiogenesis is a complex process that occurs in several stages and involves 
interactions between cells, soluble factors, and extracellular matrix molecules.  
Endothelial cells play a key role in angiogenesis.  Endothelial cells can secrete proteolytic 
enzymes which break down the basement membrane of an existing blood vessel, 
allowing the cells to invade the surrounding tissues, migrate in response to an angiogenic 
stimulus, and proliferate.  Growth factors and other soluble proteins in the ECM often 
facilitate and regulate this process, including vascular endothelial growth factor (VEGF).  
The endothelial cells form a new lumen, start to secret  extracellular matrix molecules, 
and ultimately form a new capillary (Bussolino, Mantovani, and Persico 1997; Carmeliet 
2003; Liekens, De Clercq, and Neyts 2001).  Mural cells are also recruited to the site and 
play an important role in angiogenesis.  Angiogenesis may be inhibited at any of these 
key steps (Pandya, Dhalla, and Santani 2006).  Targeting endothelial cell proliferation, 
cell migration, and chemotaxis have shown potential in ngiogenesis inhibition. 
 In the present study, we demonstrate that SsnB inhibits endothelial cell functions 
related to angiogenesis in several in vitro functional assays.  The data suggests the 
potential of SsnB as an anti-angiogenic agent by showing inhibition of human endothelial 
cell tube formation and migration.  We have also examined the effects of SsnB on 
 
20 
endothelial cell gene expression, focusing in particular on pathways related to 
angiogenesis.  In addition, our data show that SsnB arrests endothelial cell division in the 
G1 phase and downregulates the cell cycle proteins cdc6 and cyclin E2.  Overall, these 
findings add anti-angiogenic and cytostatic properties o the list of diverse effects 
exhibited by SsnB.  
Experimental Procedures 
Materials – Sparstolonin B was purified from the plant Sparganium stoloniferum 
according to previously published methods (Liang et al. 2011).  The purity of SsnB was 
determined to be greater than 99% by HPLC, and a stability test was utilized to ensure 
that samples were consistently > 99% pure. 
Cell Culture - Human coronary artery endothelial cells (HCAECs), human umbilical vein 
endothelial cells (HUVECs), and human cardiac microvascular endothelial cells 
(HMVECs) were obtained from Lonza (Hopkinton, MA) and cultured on polystyrene, 
tissue culture-treated petri plates (100 X 20 mm) coated with 0.1% gelatin.  HUVECs, 
HCAECs, and HMVECs were cultured in endothelial celmedium supplemented with 
10% fetal bovine serum (FBS) and endothelial cell mitogen / growth supplement 
(Biomedical Technologies, Stoughton, MA).  The endothelial cell medium was replaced 
every 2-3 days, and the cells were passaged after complete confluence was reached.  
Confluent plates were trypsinized and split, and the cells were cultured until the fourth 
passage was reached. 
 Matrigel Tube Formation Assay - To initially determine if SsnB inhibited pro-
angiogenic cell functions, a tube formation assay with Matrigel was performed.  Growth 
factor reduced Matrigel (BD Biosciences, Bedford, MA) was added to the wells of a 96 
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well polystyrene culture plate and incubated at 37 °C for 30 minutes.  Cells (HUVECs, 
HCAECs, or HMVECs at passage 2 to 4) were added to ach well to reach a final number 
of 20,000 cells per well.  SsnB was added to the wells at a concentration of 1, 10, or 100 
µM.  Endothelial cell medium with DMSO (0.1%) was used as a vehicle control.  Each 
group contained 4 replicates.  The plates were placed in an incubator for 4 h.  During the 
incubation, the endothelial cells formed elongated structures called cords, also known as 
tubes.  After 4 h, neutral buffered formalin was adde  to fix the cells.  Pictures of three 
non-overlapping fields were taken from each well.  The lengths of single cell endothelial 
cords were measured with Image-Pro Plus (Media Cybernetics, Silver Spring, MD), and 
the sum of tube lengths for each well was determined.  The average total length and 
standard deviation for each group were determined, an  the appropriate statistical tests 
(ANOVA and Newman-Keuls) were completed.  The tube formation assay was replicated 
three times for both HUVECs and HCAECs.  The assay w s also repeated with cardiac 
HMVECs.  
 Cell Viability - A Live/Dead assay (Invitrogen, Eugene, OR) was utilized to 
investigate the effect of SsnB on cell viability.  The Matrigel tube formation experiment 
was repeated with HUVECs in chamber slides at a concentration of 20,000 cells per well.  
The cells were treated with SsnB (1, 10, or 100 µM) or Vehicle Control (0.1% DMSO) as 
described above.  After four hours of incubation, the slides were removed.  A chamber 
slide containing HUVECs treated with 70% methanol for 30 minutes was used as a 
control for dead cell staining.  The slides were aspir ted and washed with PBS, and 
EthD-1 and calcein AM were added to each well.  Theplates were incubated in the dark, 
and images were taken with a light microscope at 10X magnification.. 
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 Transwell Insert Cell Migration Assay - The cell invasion assay was performed 
with a Transwell insert system (6.5 mm diameter inserts with 8.0 µm pores in a 
polycarbonate membrane situated in wells of 24 wellpolystrene, tissue culture treated 
plates, Corning Incorporated, Corning, NY ).  The Transwell inserts were coated with 
0.1% gelatin for 30 min and incubated in low serum medium for 1 h.  Cultured HUVECs 
were trypsinized and then resuspended in low serum medium (0.5% fetal bovine serum 
without endothelial cell mitogen), and added at 50,00  cells per insert.  The cells were 
allowed to adhere to the inserts for 30 min.  Next, various concentrations of SsnB 
(0.0001, 0.001, 0.01, 0.1, 1, 10, and 100 µM) or vehicl  control (0.1% DMSO) were 
added to the Transwell inserts.  After 30 min, the medium in the lower chamber for the 
experimental groups was replaced with low serum medium containing 10 ng/ml VEGF, 
establishing a chemoattractant gradient between the top insert and lower chamber.  For 
the negative control group, the medium was replaced with low serum medium (0.5% fetal 
bovine serum).  The plates were incubated for 8 h at 37°C.  During the incubation, the 
cells migrated through the pores of the Transwell insert towards the lower chamber.  At 
the end of this period, cells on the upper surface of the insert were removed, and migrated 
cells on the bottom side were fixed in formalin and stained with Hoechst dye (a 
fluorescent nuclear stain).  The filter inserts were removed from the wells and mounted 
on glass slides.  Cells were counted from four random fields observed with a 10X 
objective lens.  The cell migration experiments were repeated three times at high SsnB 
concentrations (0.1, 1, 10, 100 µM) and one time at low SsnB concentrations (0.0001, 
0.001, 0.01, 0.1 µM) for HUVECs. 
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 Cell Cycle Analysis - Cell cycle analysis was performed using propidium odide 
staining and flow cytometry.  HUVECs (approximately 75% confluent) cultured in 6 well 
polystyrene culture plates coated with 0.1% gelatin were serum starved for 24 hours in 
low serum medium containing 0.5% fetal bovine serum and no endothelial cell mitogen 
to synchronize the cells in the G0/G1 phase.  After 24 hours, the low serum medium was 
replaced with treatments of either 100 µM SsnB or vehicle control (0.1% DMSO) diluted 
in complete growth medium (10% fetal bovine serum with endothelial cell mitogen) in 
triplicate.  The treated cells were incubated for 24, 30, and 36 hours.  After incubation, 
the cells were trypsinized, transferred to 5 ml polysytrene round bottom tubes (12 X 75 
mm), and centrifuged.  The medium was aspirated, an the cells were washed with PBS.  
After fixing the cells with ice-cold 70% ethanol for 15 min, the cells were centrifuged 
and stained with propidium iodide for 30 min.  The samples were then analyzed with a 
flow cytometer (Beckman Coulter FC500).  The unstained and stained cell groups were 
used to calibrate the settings on the flow cytometer.  The data were collected and 
analyzed with ModFit software. 
 Microarray Analysis - Confluent plates (100 X 20 mm polystyrene, tissue c lture-
treated petri plates coated with 0.1% gelatin, 75% confluent) of HUVECs and HCAECs 
(four plates for HUVECs, n=2, and six plates for HCAECs, n=3) were chosen for the 
microarray experiments.  Half of the plates received complete growth medium (10% fetal 
bovine serum with endothelial mitogen) containing vehicle control (0.1% DMSO), and 
the remaining plates received complete growth medium containing 100 µM SsnB.  The 
plates were incubated for 24 h to allow SsnB to have an effect on cellular gene 
expression.  Following incubation, RNA isolation was completed with the RNeasy Mini 
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kit from Qiagen.  The cells were lysed, and RNA was isolated by using the RNeasy spin 
columns and following the protocol provided by Qiagen.  Purified RNA was sent to the 
Medical University of South Carolina Proteogenomics Facility for microarray analysis.  
The GeneChip Human Genome U133 Plus 2.0 Array was utilized to track changes in 
gene expression due to SsnB treatment.  Complete data was uploaded to the NCBI Gene 
Expression Omnibus database (accession number GSE44598). 
 Real Time RT-PCR - After a careful analysis of the microarray data, key genes 
(CDC6, CCNE2, KITLG, ALDH3A1, CCNB1, CDC2, HMMR, DIAPH3, ANLN, and 
CDKN3) were chosen for quantitative real-time PCR (q T-PCR) to verify the gene 
expression results.  HCAECs and HUVECs were exposed to SsnB or vehicle control for 
24 h (as previously described in the microarray section).  For RT-PCR, RNA was isolated 
from the cells with the RNeasy Mini kit as described previously.  After forward and 
reverse primer kits (Qiagen, Valencia, CA) were select d, the RNA was amplified.  The 
one-step RT-PCR reactions were completed on the BioRad iCycler thermal cycler system 
in the Instrumentation Resource Facility at the USC School of Medicine.  The expression 
levels were normalized, and RNA levels were quantified. 
 Data Analysis - Microarray data analysis, including data normalization (robust 
multi-array average), identification of differentially expressed genes (comparative 
analyses with dChip software), and heat map construction, was carried out to determine 
how SsnB affects gene expression and affected pathways (n = 2 for HUVECs and n = 3 
for HCAECs).  After a careful analysis of the microa ray data, several key genes were 
chosen for qRT-PCR to verify the gene expression results.  The genes were chosen based 
on the following criteria:  fold change ≥ 2, p < 0.05, unpaired t-test with a false discovery 
 
25 
rate approximating 0%, appearing in both data sets (HUVECs and HCAECs), and gene 
function relating to cell proliferation and/or angio enesis.  For qRT-PCR, the expression 
levels were normalized to the housekeeping gene GAPDH, and RNA levels were 
compared between groups with the ∆∆Ct method. 
Results 
 SsnB inhibits endothelial cell tube formation and cell migration - Figures 2.1 and 
2.2 show representative results from the tube formation and cell migration assays with 
HUVECs.  SsnB treatment resulted in a dose-dependent inhibition of HUVEC tube 
formation at concentrations between 1 and 100 µM (p < 0.05, Newman-Keuls test).  SsnB 
also demonstrated a dose-dependent inhibition of VEGF-induced cell migration at 
concentrations between 0.0001 and 0.1 µM (p < 0.05), which leveled off between 0.1 and 
100 µM (p < 0.05).  Experiments with HCAECs also demonstrated a dose-dependent 
inhibition (between 1 and 100 µM) of endothelial cel tube formation on the substrate 
Matrigel (Figure 2.1).  A dose-dependent inhibition of tube formation was also seen with 
cardiac HMVECs (see Appendix, Figure A.2).  Results from the live/dead assay with 
HUVECs showed that SsnB had no effect on cell viability at the concentrations used.  
Cells treated with SsnB or vehicle control showed positive staining for live cells, but no 
staining for dead cells (red fluorescence).  These data suggest that SsnB is able to inhibit 
endothelial cell morphogenesis and that cell migraton, a crucial process in angiogenesis, 
may play a role. 
  
 
Figure 2.1  SsnB inhibits endothelial cell tube formation on Matrigel. A. Total tube 
length as a function of SsnB concentration in HUVECs. B. Total tube length as a function 
of SsnB concentration in HC
Representative micrographs demonstrating tube formation in HUVECs (left 










Figure 2.2  SsnB inhibits endothelial cell migration.
SsnB concentration (0.1 to 100 µM). B. Migrated cells as a function of SsnB 
concentration (0.0001 to 0.1 µM) shows a dose
control, Newman-Keuls test. C. Representative micrographs demonstrating cell migra





  A. Migrated cells as a fu
-dependent response. *p < 0.05 vs. vehicle 







 SsnB arrests endothelial cells in the G1 phase of the cell cycle - Figure 2.3 depicts 
representative results from the cell cycle experiments.  In comparison to vehicle controls, 
flow cytometric cell cycle analysis of HUVECs treatd with SsnB showed an increase of 
cells in the G1 phase and a decrease of cells in the S phase after 24, 30, and 36 hours of 
treatment.  In untreated cells, the percentage of clls in S phase decreased and the 
percentage in G2/M increased from 24 to 36 hours after ddition of growth medium, as 
expected once cells begin to re-enter and move throug  the cell cycle. Overall, these 
results imply that endothelial cells are being arrested in the G0/G1 phase, suggesting an 





Figure 2.3  SsnB arrests endothelial cells in the G1 phase of the cell cycle. A. After 24, 
30, and 36 hours of treatment, 100 µM SsnB decreased the percentage of cells in the S 
phase and increased the percentage of cells in the G1 phase. *p < 0.005 vs. corresponding 
vehicle control, Newman-Keuls test. B. Representative cell cycle data demonstrating the 
increase in G1 cell percentage and decrease in S phase cell percentage after 24 hours of 
SsnB treatment (left - vehicle control, right - SsnB) 
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 SsnB changes the expression of genes associated with cell cycle and cell 
proliferation - Microarray experiments demonstrated differential expression of several 
hundred genes in response to SsnB exposure (916 genes for HUVECs and 356 genes for 
HCAECs, fold change ≥ 2, p < 0.05, unpaired t-test with a false discovery rate 
approximating 0%).  Supplementary Table A.1 and Supplementary Table A.2 present the 
results of the gene function enrichment analysis for HUVECs and HCAECs, respectively.  
Overall, microarray data from both cell types showed significant overlap, including genes 
in pathways associated with cell proliferation, cytoskeleton, chemotaxis, and cell cycle, 
all areas implicated in angiogenesis.  These results are consistent with the data obtained 
from the cell migration and cell cycle functional studies.    From this microarray study, it 
is clear that SsnB regulates genes involved in angiogenic processes in HUVECs and 
HCAECs. 
 Real Time RT-PCR - Following microarray data analysis, key genes (listed in 
Table 2.1) were chosen for verification with real time RT-PCR.  Cyclin E2 (CCNE2) and 
Cell division cycle 6 (CDC6) are regulatory proteins that control cell cycle progression 
through the G1/S checkpoint.  Both CCNE2 and CDC6 were downregulated in the 
microarray data.  qRT- PCR confirmed that gene expression of CCNE2 and CDC6 was 
downregulated after SsnB exposure to 64% and 35% of controls respectively for 
HUVECs and to 57% and 14% of controls respectively for HCAECs.  Kit-Ligand 
(KITLG), also known as stem cell factor, is a protein involved in the differentiation and 
growth of stem cells.  Aldehyde dehydrogenase 3 family, ember A1 (ALDH3A1) is a 
protein involved in the aryl hydrocarbon receptor pathway.  These genes were chosen for 
further study because they were highly upregulated by SsnB treatment in the microarray 
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data set. In HUVECs, qRT-PCR analysis demonstrated that KITLG and ALDH3A1 
expression was upregulated to 400% and 1280% of controls, respectively.  In HCAECs, 
KITLG and ALDH3A1 expression was upregulated to 260% and 4620% of controls, 
respectively.  The microarray data was supported in both data sets. 
Table 2.1  Comparison of RT-PCR and Microarray Results.  Fold expression change vs. 
vehicle control. 
 















KITLG 4.0 6.2 0.02795 2.6 2.1 0.00010 
ALDH3A1 12.8 7.7 0.00609 46.2 8.8 0.00001 
HMMR 0.24 0.11 0.03073 0.062 0.20 0.00006 
DIAPH3 0.19 0.34 0.03248 0.26 0.38 0.00019 
ANLN 0.20 0.09 0.00900 0.13 0.11 0.000001 
CDKN3 0.18 0.19 0.01471 0.22 0.18 0.00018 
CCNB1 0.40 0.19 0.02304 0.13 0.16 0.00003 
CDC2 0.14 0.08 0.00440 0.17 0.20 0.00004 
CDC6 0.35 0.23 0.01527 0.14 0.18 0.00185 
CCNE2 0.64 0.24 0.01814 0.57 0.38 0.00180 
 
Discussion 
 Pathological angiogenesis is associated with many disorders, including 
rheumatoid arthritis, diabetic retinopathy, and psoriasis.  Recent research has shown that 
inhibiting angiogenesis may prove to be an effective herapeutic option in treating these 
disorders.  In the present study, potential anti-angiogenic effects of SsnB were 
demonstrated in several in vitro functional assays with endothelial cells, including the 
Matrigel tube formation assay and the Transwell insert cell migration assay.  SsnB was 
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also shown to arrest endothelial cells in the G1 phase of the cell cycle.  The cellular 
functions tested in these assays represent key steps in angiogenesis that are inhibited by 
SsnB, including cell proliferation, cell migration, and chemotaxis.  To further investigate 
the mechanism of action for SsnB, we utilized microar ay analysis to examine how SsnB 
affected gene expression in endothelial cells.  After SsnB exposure, genes associated with 
cell proliferation, cell cycle, chemotaxis, and thecytoskeleton were differentially 
regulated in both HUVECs and HCAECs.  Our data suggest that SsnB alters gene 
expression in these pro-angiogenic pathways. 
 Targeting endothelial cell proliferation has shown potential in the area of 
angiogenesis inhibition.  Endothelial cell proliferation may be inhibited in numerous 
ways, including the downregulation of cell cycle regulatory proteins (Pandya, Dhalla, and 
Santani 2006).  Cyclins and cyclin dependent kinases r  regulatory proteins that control 
progression through the cell cycle by regulating specific cell cycle checkpoints.  Cyclins 
help activate cyclin dependent kinases, which phosprylate downstream proteins that 
allow cells to progress through these checkpoints.  Cyclin E2 (CCNE2) and Cell division 
cycle 6 (CDC6) are regulatory proteins that control pr gression through the G1/S 
checkpoint.  CDC6 regulates DNA replication, and cyclin E2 activates cyclin-dependent 
kinase 2 (Wu et al. 2009; Borlado and Mendez 2008).  Downregulation of CCNE2 and 
CDC6 will trap cells at the G1/S checkpoint and prevent endothelial cells from initiating 
DNA replication.  The cell cycle regulatory proteins, Cyclin E2 (CCNE2) and Cell 
division cycle 6 (CDC6), were both downregulated by SsnB treatment.  Overall, our data 
suggest that SsnB downregulates the cell cycle regulatory proteins CCNE2 and CDC6, 
potentially trapping cells in the G1 phase and hindering cell proliferation, an important 
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step in angiogenesis (Nigg 2001; Sullivan and Morgan 2007; Tassan et al. 1994; O'Farrell 
2001). 
 Our data shows that SsnB affects the gene expression of additional cell cycle 
regulatory proteins, including cyclin B1 (CCNB1) and cyclin dependent kinase 1 
(CDC2).   CCNB1 and CDC2 are regulatory proteins that control progression through the 
G2/M checkpoint.  Downregulation of CCNB1 and CDC2 will trap cells at the G2/M 
checkpoint and prevent endothelial cells from enteri g the final stages of cell division.  
Table 2.1 demonstrates that CCNB1 and CDC2 were both downregulated by SsnB.  In 
addition to preventing cell progression through the G1/S checkpoint, SsnB may also 
prevent progression through the G2/M checkpoint by downregulating these additional 
cell cycle proteins (Nigg 2001; Sullivan and Morgan 2007; Tassan et al. 1994; O'Farrell 
2001).  This effect is less readily seen due to blockage at the G1/S checkpoint.      
 Sparganium stoloniferum has long been used in Traditional Chinese Medicine for 
the treatment of cancer and seizures.  Major chemical components from the stem and 
rhizome, including flavonoids, saponins, and phenylpropanoids, are responsible for these 
therapeutic effects (Li et al.).  Anti-tumor agents often exhibit anti-angiogenic effects, 
among other cancer suppressing properties.  Inhibiting angiogenesis cuts tumors off from 
the vasculature, limiting growth and metastasis (Meng t al.).  Previously published 
research has shown that extracts derived from Sparganium stoloniferum have 
demonstrated potent anti-cancer effects.  Isolated ch mical compounds from this herb, 
including a sucrose ester, a phenylpropanoid glycerol, carboxylic acid esters, and a 
phenylpropanoid glycoside, demonstrated anti-tumor activities (Xiong et al. 2009; Lee et 
al.).  In addition, the polyphenolic structure of SsnB also reveals much about its potential 
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therapeutic effects.  Many plant-derived polyphenols have demonstrated anti-
inflammatory and anti-angiogenic properties.  Quercetin and resveratol, both polyphenols 
isolated from red wine, have demonstrated anti-inflammatory and anti-angiogenic 
properties.  In addition, oleuropein and hydroxytyrosol, both derived from virgin olive 
oil, reduce angiogenesis by inhibiting matrix metalloproteinase-9 (MMP-9) and 
cyclooxygenase-2 (COX-2) (Scoditti et al. 2012).  Emodin, another plant-derived 
polyphenol similar to SsnB, has also been shown to i hibit angiogenesis by targeting 
endothelial cell proliferation (Kwak et al. 2006).  Emodin causes a downregulation of 
CCNB1 and CDC2 and a cell cycle arrest at the G2/M phase (Wang, Wu, and Zhen 
2004).  
 In addition to its effects on the cell cycle and cell proliferation, SsnB also affects 
other key steps of angiogenesis, including cell migrat on and chemotaxis.  The 
microarray data for both HUVECs and HCAECs demonstrates an enrichment of genes 
associated with both pathways, including diaphanous homolog 3 (DIAPH3), hyaluronan-
mediated motility receptor (HMMR), and anillin (ANL), an actin binding protein.  
Furthermore, it is also important to investigate potential upstream pathways that lead to 
the alterations in gene expression seen in the microarray data.  Previously published data 
have shown that SsnB can suppress the NF-κB pathway, and prior studies have 
demonstrated a link between NF-κB signaling and expression of cell cycle proteins.  
Genes for these regulatory proteins, such as CCNE2, CDC6, CCNB1, and CDC2, contain 
binding sites for NF-κB (Hsu, Lee, and Pan; Cude et al. 2007; Liu et al. 2009; Wang et 
al.; Meteoglu et al. 2008).  SsnB may suppress the NF-κB pathway and cause a 
subsequent downregulation of the cell cycle regulatory proteins CCNE2 and CDC6.  
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SsnB has also been shown to inhibit the MAPK pathways, including JNK, ERK, and p38 
signaling, which all affect gene expression and cell proliferation.  We need to explore 
these relationships as potential mechanisms of angiogenesis inhibition. 
 Our current study with HUVECs and HCAECs demonstrates that SsnB inhibits 
angiogenic processes in functional assays, including the Matrigel tube assay, Transwell 
insert cell migration assay, and microarray analysis.  Our next step is to demonstrate the 






THE UTILIZATION OF THE CHICK CHORIOALLANTOIC MEMBRANE ASSAY TO EXAMINE THE 
EX VIVO ANTI-ANGIOGENIC EFFECTS OF SPARSTOLONIN B. 
Abstract 
 Pathological angiogenesis plays a significant rolein many disorders, including 
atherosclerosis, diabetic retinopathy, and cancer.  Inhibiting angiogenesis may offer a 
potential treatment for angiogenesis-dependent disor ers.  Sparstolonin B (SsnB), a novel 
bioactive compound isolated from Sparganium stoloniferum, has demonstrated the ability 
to inhibit pro-angiogenic functions in endothelial cells.  In functional assays, SsnB 
inhibited endothelial cell tube formation (Matrigel method) and cell migration (Transwell 
method) in a dose-dependent manner.  Microarray experiments with human umbilical 
vein endothelial cells (HUVECs) and human coronary artery endothelial cells (HCAECs) 
demonstrated differential expression of genes associated with cell proliferation and cell 
cycle.  SsnB may exert its anti-angiogenic properties by downregulating CCNE2 and 
CDC6, halting progression through the G1/S checkpoint.  To investigate the effects of 
SsnB on ex vivo angiogenesis, a chick chorioallantoic membrane (CAM) assay was 
utilized.  Chick embryos were exposed to methylcelluose discs containing vehicle control 
(DMSO) or 100 micromolar SsnB.  Chick embryos receiving SsnB discs showed 
significant reduction in capillary length and branching number relative to the vehicle 
control group.  Overall, SsnB caused a significant reduction in angiogenesis, 




 Angiogenesis refers to capillary formation from existing blood vessels; it is a 
complex process that occurs in several stages and involves interactions between cells, 
soluble factors, and extracellular matrix molecules.  Endothelial cells play a key role in 
angiogenesis.  First, proteolytic enzymes break down the basement membrane of an 
existing blood vessel and endothelial cells invade the surrounding tissues, migrate, and 
proliferate.  Growth factors and other soluble proteins in the ECM, including Vascular 
Endothelial Growth Factor (VEGF), facilitate and regulate this process.  After migration 
and proliferation, the endothelial cells form a new lumen and start to secrete extracellular 
matrix molecules, ultimately forming a new capillary.  Supporting cells, such as pericytes 
and smooth muscle cells, and extracellular matrix proteins are also extensively involved 
in the process (Bussolino, Mantovani, and Persico 1997; Carmeliet 2003; Liekens, De 
Clercq, and Neyts 2001). 
 Angiogenesis plays an important role in many normal physiological functions and 
numerous pathological conditions.  Physiological processes include embryonic 
development, wound healing, and changes in the endometrial wall.  Pathological 
processes that involve angiogenesis include atheroscl r is, psoriasis, rheumatoid 
arthritis, and tumor growth and metastasis.  Targetin  angiogenesis may provide a 
potential therapy for these pathological disorders.  Angiogenesis may be inhibited at 
multiple steps.  Growth factors, including Vascular Endothelial Growth Factor and basic 
Fibroblast Growth Factor, are a suitable target.  Current approaches to sequester VEGF 
include soluble VEGF receptors and neutralizing antibodies against VEGF.  Intracellular 
signaling molecules, including tyrosine kinases, can be inhibited to prevent receptor-
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mediated activation of endothelial cells.  There also exist natural angiogenesis inhibitors, 
including endostatin, retinoids, and fibronectin fragment, which may be targeted for 
angiogenesis inhibition.  Angiogenesis inhibitors often target endothelial cells through 
the inhibition of cell proliferation, migration, and protease production (Pandya, Dhalla, 
and Santani 2006).  Current research into angiogenesis inhibition has demonstrated ways 
to limit atherosclerosis.  By inhibiting intraplaque angiogenesis, necessary factors, such 
as inflammatory cells and mediators, are not delivered to the growing plaque, diminishing 
plaque growth.  Plaque stability may also improve, decreasing the likelihood of plaque 
rupture and subsequent thrombosis and stroke or myocardial infarction (Virmani et al. 
2005; Moreno et al. 2004; Sridhar and Shepherd 2003). 
 Sparstolonin B (SsnB) is a novel compound isolated from the plant Sparganium 
stoloniferum, a perennial, aquatic plant grown in North and East China.  Dried powder 
and extracts derived from Sparganium stoloniferum have been used for centuries in 
Chinese folk medicine for the treatment of inflammatory diseases, seizures, and blood 
stasis.   These compounds are also widely used to treat gynecological problems, including 
amenorrhea and cancer, such as hysteromyoma.  Most significantly, one such extract has 
shown the ability to inhibit angiogenesis and estrogen-mediated activities (Sun, Wang, 
and Wei 2011).  Extracts containing active components are isolated from the root-like 
modified stem of the plant, known as the rhizome or tuber.  A typical extraction protocol 
involves drying the rhizome and grounding it into a powder.  The powder is mixed in 
boiling distilled water to produce an aqueous soluti n.  Extracts may also be prepared 
with organic solvents, including ethanol, choloroform, and ethyl acetate.  Extracts contain 
a multitude of active components including flavonoids, phenylpropanoid glycosides, 
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aromatic acids, and polyphenols (Wu et al. 2012).  Sparstolonin B isolation was begun by 
soaking the powdered tuber in 85% ethanol overnight and extracting three times with the 
same solvent.  The solvent was filtered and concentrated under vacuum, producing a 
residue, which was then dissolved in water and extracted with petrol, ethyl acetate, and n-
butyl alcohol in sequential order.  This extract was run through a silica gel column and 
eluted with petrol - ethyl acetate mixtures with increasing polarities.  The end product 
was yellow needles containing SsnB (Liang et al. 2011). 
 The potential effects that SsnB may have on biologcal pathways may be revealed 
by its chemical structure.  The structure of SsnB is very similar to isocoumarin or 
xanthone, both compounds know for anti-coagulant, anti-inflammatory, and anti-tumor 
properties.  Furthermore, the polycyclic / polyphenolic structure is suggestive of the 
ability of SsnB to serve as an angiogenesis inhibitor (Liang et al. 2011).  Polyphenolic 
compounds derived from plants, including olives andgrapes, have been shown to have 
anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.  
Compounds derived from green tea and red wine, particularly quercetin and resveratrol, 
have both demonstrated angiogenesis inhibition (Scoditti et al. 2012).  Similarly, we have 
shown the ability of SsnB to inhibit in vitro angiogenesis.  In functional assays with 
endothelial cells (HUVECs, HCAECs, and HMVECs), SsnB has demonstrated the ability 
to inhibit key steps of angiogenesis, including morphogenesis, cell migration, 
chemotaxis, and cell cycle progression.  Using microarrays, we have shown that SsnB 
altered gene expression in pathways associated with the cell cycle, cytoskeleton, and 
cytokinesis.  Furthermore, published research has sown that SsnB blocks Toll-like 
 
40 
receptor 2 and Toll-like receptor 4 mediated inflammation in human and murine 
macrophages (Liang et al. 2011).     
 Preliminary research into angiogenesis inhibitors or timulators often begins with 
simple in vitro assays using endothelial cells, such as the Matrigel tube formation assay 
or Transwell insert migration assay.  However, these a says only study isolated functions 
of endothelial cells. Angiogenesis is a multicelllular event that also incorporates 
interactions with extracellular components.  In order to fully prove that a compound 
inhibits or stimulates angiogenesis, an in vivo or ex vivo assay must be utilized to address 
the complex, multicellular nature of angiogenesis.  Several commonly used in vivo assays 
include the Matrigel plug, corneal angiogenesis, and hamster cheek pouch assays.  The 
chick chorioallantoic membrane (CAM) assay is also widely used to study ex vivo 
angiogenesis.  The assay is simple and reproducible, and it reveals more important 
information than in vitro assays (Auerbach et al. 2003).  The CAM is used for gas and 
nutrient exchange in the chick embryo during development.  Figure 3.1 illustrates the 
organization of a typical CAM.  The allantois appears 3 days after incubation as an 
evagination from the endodermal hind gut.  After spreading into the extraembryonic 
coelom, the allantoic vesicle enlarges rapidly.  The mesodermal layers of the allantois 
and chorion fuse to form the chorioallantoic membrane.  This double layer becomes 
highly vascularized as blood vessels develop.  Within t e CAM, single walled immature 
blood vessels develop first, eventually forming a capillary plexus around day 8.  All 
vessels are connected to branches from the two main chorioallantoic arteries and one 
chorioallantoic vein.  At day 18, the vascular system reaches its final organization.  
Located near the porous shell, the highly vascularized CAM allows exchange of oxygen 
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and carbon dioxide and serves as an area to store wast  products, including urea and uric 
acid.  The rapidly developing vascular system in the CAM provides an ideal environment 
to study how compounds affect angiogenesis (Ribatti 2008). 
 
Figure 3.1  Chick embryo demonstrating chorioallantoic membrane vascularization. 
 In the CAM assay, test compounds are added to the surface of the CAM, and their 
effect on angiogenesis is examined.  Delivery system  include synthetic polymer discs, 
gelatin sponges, or glass coverslips.  One of the most popular methods involves the 
creation of discs made from a solution of 1% methylcellulose mixed with the test 
compound.  Methylcellulose discs allow slow release nd minimal adverse biological 
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reaction (Swiercz et al. 1999).  This assay may be completed with or without the intact 
shell (in ovo and ex ovo, respectively).  For the in ovo method, eggs are incubated for 7 to 
9 days, and a square hole is cut in the shell afterremoving albumin with a fine needle.  
Through this window, the test compounds are added.  The window is sealed, and eggs are 
placed back in an incubator for 2 or 3 days.  The in ovo method maintains a more 
physiological environment, but provides a very limited area of the CAM with which to 
work.  In the shell-less or ex ovo method, day 3-4 incubated eggs are carefully cracked 
open, and the egg contents are transferred to plastic petri plates.  The plates are incubated 
for an additional 2 to 6 days.  This is technically  whole-animal assay, even though it 
shares much in common with in vitro assays.  The x ovo method provides a large surface 
area of the CAM to place test substances and easily document with time lapse 
photography.  However, a high mortality rate is often associated with the ex ovo method, 
sometimes reaching 50% dead after the first three days (Dohle et al. 2009; Ribatti 2008; 
Auerbach et al. 2003).     
 In both assays, the angiogenic response in the CAM may be measured in 
numerous ways.  For analysis, pictures may be taken t the end of the experiment or over 
time to document the progression of blood vessel growth.  However, time progression 
photos involve excessive handling of the embryos, which increases the embryonic 
mortality rate.  Images from the area surrounding ad underneath the test compound may 
be qualitatively scored on a numeric scale, such as 0 to 4, based on vascularization.  
Qualitative analysis is quick and reproducible, but it requires initial serial dilution assays 
with controls to establish the grading scale.  Quantitative methods have proven more 
accurate and less prone to human error.  Quantitative techniques include the measurement 
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of blood vessel number, length, and area.  Another quantitative procedure involves 
counting the number of converging vessels with superimposed rings on the CAM image. 
To address blood vessel branching, the number of bifurcation points may be counted, or 
fractal pattern analysis may be utilized.  In addition, the total blood vessel volume in the 
CAM may be measured by injecting thymidine or a colorimetric / fluorescent dye.  Many 
of these quantitative techniques involve time consuming manual analysis of images, 
which can be overcome with automated analysis by computer software algorithms 
(Ribatti 2008; Blacher et al. 2001).   
 Our preliminary studies with HUVECs, HCAECs, and HMVECs have shown 
evidence of the anti-angiogenic effects of SsnB in the Matrigel tube assay and the 
Transwell insert cell migration assay.  However, we must also demonstrate the in vivo or 
ex vivo efficacy of SsnB if we would like to further evalute SsnB as a potential 
pharmaceutical agent.  The in vitro assays alone are not sufficient in this regard.  We
demonstrated the x vivo anti-angiogenic effects of SsnB with the chick chorioallantoic 
membrane (CAM) assay. 
Experimental Procedures 
Materials - Sparstolonin B was purified from the plant Sparganium stoloniferum 
according to previously published methods (Liang et al. 2011).  Fresh fertilized bovans 
eggs were obtained from Clemson University and stored at 4°C for no longer than one 
week. 
 Methylcellulose Discs - Methylcellulose discs were created with a solution of 
0.5% methylcellulose (diluted in sterile deionized water).  A methylcellulose solution of 
 
44 
100 micromolar SsnB was made by adding 1.1 microliters of stock SsnB (93 mM) to 1 
ml 0.5% methylcellulose.  A vehicle control solution was created by adding 1 microliter 
of dimethyl sulfoxide (DMSO) to 1 ml 0.5% methylcellulose.  Discs were created by 
placing 20 microliter droplets of SsnB or vehicle control solution onto 
polytetrafluoroethylene tape (to minimize adherence during drying) and allowed to dry 
under a laminar flow hood. 
 Chick Chorioallantoic Membrane Assay - The fertilized eggs were placed in a 
humidified egg incubator with forced air circulation at 37°C.  The eggs were 
automatically rotated every three hours.  After 4 days of incubation, the eggs were 
removed and cracked.  Chick embryos with intact yolks were placed in 100 mm petri 
plates.  Each petri plate was placed in a weigh boat c ntaining 13 ml Moscona’s buffer 
and covered with cellophane wrap with two holes for air circulation.  The plates were 
placed in a water-jacketed incubator (37C, 5% CO2) for 2 days.  After 2 days of 
incubation, the methylcellulose discs containing either SsnB or vehicle control were 
placed on top of the CAM of each embryo in the right upper quadrant in an area near the 
allantoic vessels.  After 2 additional days of incubation, the CAMs were examined and 
photographed with a dissecting stereomicroscope.  Images were taken of areas containing 
the discs and non-treated regions.  Each group contained seven embryos (calculated with 
PS 3.0.5 software, effect size of 50%, standard deviation of 30%, statistical power of 0.8, 
and α=0.05).  The CAM assay was completed two times.    
 Image Analysis - Images were analyzed with Image-Pro Plus software.  Blood 
vessel length and branching number were utilized to measure the effect of SsnB on 
angiogenesis.  The vessel length was measured for areas containing the discs and non-
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treated regions.   Normalized vessel length was calculated by dividing the length values 
of the treated regions by those of the non-treated regions.  The same process was repeated 
for measuring the branching number.   
 Statistical Analysis - To determine if a statistically significant difference between 
the treatment groups in each experiment existed, a one-way analysis of variance test 
(ANOVA) was completed.   
Results 
 SsnB inhibits angiogenesis in the CAM assay - Initial in vitro studies with SsnB 
and endothelial cells have demonstrated the ability of SsnB to inhibit important cellular 
aspects of angiogenesis, including tube formation, cell migration, cell cycle progression, 
and chemotaxis.  However, these in vitro results were not conclusive in proving the anti-
angiogenic properties of SsnB.  We utilized a chick chorioallantoic membrane assay to 
successfully demonstrate that SsnB inhibits ex vivo angiogenesis.  The results from the 
CAM assay are depicted in Figure 3.2.  Overall, SsnB resulted in a significant decrease in 





Figure 3.2  SsnB reduces normalized blood vessel length in the CAM assay. 
 In addition to inhibiting blood vessel length, SsnB also caused a significant 
decrease in the normalized branch number.  The results are depicted in Figure 3.3.  
Compared to the vehicle control, SsnB decreased the number of points where blood 
vessels branched into two or more separate vessels.  Interestingly, it has been shown that 
macrophage production of matrix metalloproteinases i  important for blood vessel 
























Figure 3.3  SsnB reduces normalized branch number in the CAM assay 
 Representative images of the CAM from the SsnB and vehicle control groups 
after two days of treatment are shown in figure 3.4.  The methylcellulose discs released 
SsnB or vehicle control and were still present at the end of the experiment, as complete 
biodegradation did not occur.  The transparency of the methylcellulose discs allowed 
easy imaging of the vascular network underneath the discs.  Images were taken of regions 
of the CAM that received methylcellulose discs as well as regions that did not receive 
discs.  For each embryo, the blood vessel length and branch number were measured for 
both treated and non-treated areas.  A normalized value was calculated by dividing the 
treated areas by the non-treated areas.  This approch allowed us to compensate for 
natural variations in vascular density among embryos that normally occur without the 





























fewer blood vessels, smaller vessel lengths, and fewer branches.  The methylcellulose 
discs with SsnB not only inhibited angiogenesis in the area underneath the disc, but also 
demonstrated inhibition in the immediate area surrounding the discs.  Compared to the 
SsnB group, the vehicle control group exhibited higher vessel lengths, more vessels, and 
more vascular branching.  Furthermore, SsnB treatment was associated with a decrease in 
blood vessel diameter and size.  
 
Figure 3.4  Representative images from CAM assay. 
 In addition, SsnB had no effect on the viability or morphology of the embryos 
relative to the vehicle control.  Both groups experienced similar number of embryo 
deaths, which is typically encountered with the CAM assay.  The embryos that survived 
until the end of the experiment exhibited no obvious differences in size or morphology 
between the two groups. 
Discussion 
 We demonstrated that SsnB inhibits endothelial cell functions related to 
angiogenesis in several in vitro functional assays.  The data suggests the potential of 
SsnB as an anti-angiogenic agent by showing inhibition of human endothelial cell tube 
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formation, migration, and chemotaxis.  We have alsofound evidence supporting the 
cytostatic nature of SsnB by showing that it inhibits endothelial cell progression through 
the cell cycle.  In this work, we have also demonstrated that SsnB inhibits ex vivo 
angiogenesis in the CAM assay. 
 Angiogenesis is a complex process comprised of numerous steps.  The process is 
initiated by endothelial activation, often by growth factors, such as VEGF and FGF.  
Activated endothelial cells proliferate, secrete proteases, and migrate, eventually forming 
capillary tubes with complete lumens.  Each of these steps may serve as a potential target 
for anti-angiogenic agents.  SsnB is capable of inhib ting angiogenesis by targeting 
multiple steps in the angiogenesis pathway (Roy et al. 2006).  We have previously shown 
that SsnB is capable of inhibiting tube formation and cell migration in the Matrigel tube 
assay and Transwell insert migration assay, respectively.  We have also shown SsnB 
arrests endothelial cell division in the G1 phase of the cell cycle with associated 
downregulation of the cell cycle regulatory proteins, cdc6 and cyclin E2.  This cell cycle 
arrest allows SsnB to act as a cytostatic agent, slowing endothelial division.  Finally, we 
have shown that SsnB inhibits ex vivo angiogenesis in the CAM assay.  The evidence to 
date suggests that SsnB is an effective inhibitor of angiogenesis, and may prove to be a 
suitable therapeutic alternative to treat disorders in which excessive blood vessel growth 
contributes to the pathology, including cancer, rheumatoid arthritis, and psoriasis 
(Mombeinipour et al. 2013).  SsnB may particularly be suited to treat atherosclerosis due 
to its combined anti-angiogenic and anti-inflammatory properties.  Inhibiting 
angiogenesis may prevent intraplaque angiogenesis, thereby  limiting plaque growth, 
destabilization, and subsequent rupture.  At the same time, SsnB may inhibit the chronic 
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inflammatory reactions necessary for plaque formation and growth (Moreno et al. 2004; 
Virmani et al. 2005). 
 SsnB is derived from the plant, Sparganium stoloniferum, an aquatic herb that has 
been used to treat a multitude of disorders including cancer.  Past research with this herb 
has demonstrated its use to treat cancer, seizure disorders, and inflammatory diseases 
(Wu et al. 2012).  Especially relevant to our research, Sun et al demonstrated the anti-
angiogenic effects of an aqueous extract from Sparganium stoloniferum.  In their 
research, pregnant mice were administered the aqueous extract, and the offspring from 
these mice were examined and compared to controls.  The offspring exhibited numerous 
morphological abnormalities, related to disrupted angiogenesis and estrogen signaling, 
including limb, heart, vertebral, and craniofacial defects.  FGF and VEGF levels were 
lowered in the offspring, causing decreased angiogenesis.  A disruption in FGF signaling 
is also known to cause defects in limb bud and cranial formation and heart development.  
Anti-estrogen activity was implicated in increased numbers of male offspring relative to 
female offspring.  The aqueous extract utilized in Sun’s research contained a multitude of 
active components (Sun, Wang, and Wei 2011).  Our research only focused on one 
particular active compound from Sparganium stoloniferum. 
 Prior research with SsnB has demonstrated its ability to inhibit inflammation.  
Specifically, SsnB was shown to inhibit Toll-like Receptor 2 (TLR-2) and Toll-like 
Receptor 4 (TLR-4) mediated inflammation, by acting as an antagonist to both receptors.  
Inflammatory cytokine production from lipopolysaccharide (LPS)-treated macrophages 
and mice was inhibited by SsnB treatment.  SsnB inhib ts toll-like receptors 
intracellularly, somewhere between ligand binding ad immediate adaptor recruitment 
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(for example, MyD88).  SsnB may act directly on TLR2 and TLR4 TIR domains or 
TIRAP/mal protein, which is an indispensable adaptor bridging TLR2/TLR4 TIR domain 
and MyD88 interaction (Liang et al. 2011).  Toll-like receptors are mainly involved in the 
innate immune system, where they activate inflammatory pathways to deal with 
pathogens.  However, toll-like receptors have also been shown to be implicated in cancer 
cell proliferation and metastasis.  Functional TLRs are expressed on many different 
tumor cell types; their activation stimulates cell proliferation and escape from apoptosis.  
TLRs may also enhance expression and activation of metalloproteinases and integrins, 
resulting in increased cancer cell invasion and metastasis.  TLR signaling may also 
provide cancer cells with resistance to the host immune system through upregulation of 
immunosuppressive molecules and inhibitory cytokines (Huang et al. 2008).  Overall, 
SsnB blocks the TLR signaling pathway, preventing many of the steps described above, 
some of which are also important in angiogenesis.  Thus, it is conceivable that SsnB may 
block cancer progression by multiple mechanisms in addition to inhibiting angiogenesis. 
 SsnB crosses the cell membrane and works intracellularly to suppress signaling 
pathways.  Previously published data has shown that SsnB can suppress the NF-κB 
pathway, and prior studies have demonstrated a link between NF-κB signaling and 
expression of cell cycle proteins.  Genes for these r gulatory proteins, such as CCNE2, 
CDC6, CCNB1, and CDC2, contain binding sites for NF-κB.  SsnB may suppress the 
NF-κB pathway and cause a subsequent downregulation of the cell cycle regulatory 
proteins CCNE2 and CDC6.  SsnB has also been shown to inhibit the MAPK pathways, 
including JNK, ERK, and p38 signaling, which all affect gene expression and cell 
proliferation.  In the future, we need to explore th se relationships as potential 
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mechanisms of angiogenesis inhibition (Hsu, Lee, and Pan; Cude et al. 2007; Liu et al. 
2009; Wang et al.; Meteoglu et al. 2008; Liang et al. 2011).   
 We hypothesize that the main activity of SsnB involves a cytostatic effect 
whereby it limits endothelial cell cycle progression by trapping cells in the G1 phase of 
the cell cycle.  This is accomplished by downregulating two key regulatory proteins, cdc6 
and cyclin E2, that are necessary to progress beyond the G1/S checkpoint.  As a result 
endothelial cell progression through the cell cycle is slowed down, limiting necessary cell 
proliferation required for angiogenesis.  Emodin, a structurally similar plant-derived 
polyphenol, has also been shown to inhibit angiogenesis by targeting endothelial cell 
proliferation (Kwak et al. 2006).  Emodin causes a downregulation of CCNB1 and CDC2 
and a cell cycle arrest at the G2/M phase (Wang, Wu, and Zhen 2004).    
 In addition, we also hypothesize that SsnB may inhib t endothelial cell migration 
and tube formation, additional steps required for angiogenesis, by modulating 
cytoskeletal reorganization. The microarray data for both HUVECs and HCAECs 
demonstrates an enrichment of genes associated with cell motility and cytokinesis, 
including cytoskeleton associated protein 2-like (CKAP2L), diaphanous homolog 3 
(DIAPH3), hyaluronan-mediated motility receptor (HMMR), and anillin (ANLN), an 
actin binding protein.  All four genes are involved with the cytoskeleton, cytokinesis, and 
stress fiber formation (Piekny and Maddox 2010; Yang et al. 2007; Yang et al. 2010).  In 
the tube formation experiments, SsnB seemed to change cell shape, and this may be 
caused by changes in the cytoskeleton.  We need to further investigate how SsnB affects 
endothelial cell shape, cytoskeleton arrangement, and stress fiber formation, and how 
cytoskeletal effects interact to reduce cell migration and tube formation. 
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 Furthermore, the CAM assay allowed us to examine the effects of SsnB on 
additional cell types beyond endothelial cells.  Multiple cell types are involved in 
angiogenesis, including endothelial cells and supporting cells, such as pericytes, smooth 
muscle cells, macrophages, and myofibroblasts.  Since our initial in vitro experiments 
only involved endothelial cells, we utilized the CAM assay to address the multicellular 
nature of angiogenesis.  We are particularly interest d in how SsnB affects macrophages.  
In the CAM assay, SsnB inhibited blood vessel branching.  It has been demonstrated that 
macrophage production of matrix metalloproteinase-9 (MMP-9) plays an important role 
in vascular branching during neovascularization (Johns n et al. 2004).  Prior research has 
shown that SsnB blocks TLR-2 and TLR-4 mediated inflammation in human and murine 
macrophages.  Furthermore, TLR signaling activates MMP production in macrophages 
(Huang et al. 2008).  We hypothesize that SsnB blocks TLR signaling and subsequently 
inhibits macrophage MMP-9 production required for blood vessel branching.  Additional 
experiments could examine this relationship between SsnB, TLR signaling, macrophage 
production of MMP-9, and vascular branching.  
 Overall, SsnB exhibits many diverse effects, including anti-angiogenic, and 
cytostatic properties, which may contribute in part to he traditionally reported results of 





 Angiogenesis plays an important role in physiological and pathological processes. 
Unregulated angiogenesis contributes to many pathological conditions, such as 
rheumatoid arthritis, psoriasis, retinopathy, and tumor growth and metastasis.  
Angiogenesis also plays a significant role in atherosclerosis.  Capillary networks within 
atherosclerotic plaques can serve as a source of inflammatory cells and mediators, 
promoting plaque formation.  Recent research has suggested that inhibiting angiogenesis 
may improve plaque stability and decrease plaque formation by limiting this supply of 
necessary factors to the growing plaque (Griffioen and Molema 2000). 
 Complementary and alternative medicine is a growing area of research which may 
hold the key to treatment of numerous disorders, including ones associated with 
angiogenesis.  Researchers have often looked towards herbal medicine, which has been 
used in many countries throughout the world for centuries, for sources of biologically 
active molecules.  Herbal remedies play a large rol in Traditional Chinese Medicine, 
where plants and plant-derived extracts and compounds are used to treat a multitude of 
disorders.  Many plants secrete bioactive compounds as a defense mechanism to deal 
with pests.  These bioactive compounds exhibit an array of effects, including cytotoxic or 
cytostatic properties.  Many modern day drugs have been isolated and characterized from 
these plants, which have played a large role in Traditional Chinese Medicine (Qin and Xu 
1998; Zhou and Wu 2006).
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 One such herb, Sparganium stoloniferum, has been extensively used in Chinese 
herbal medicine to treat a variety of disorders, including seizures, amenorrhea, and 
cancer.  Sparganium stoloniferum is an aquatic plant which grows in the northern and
eastern regions of China (Wu et al. 2012; Sun, Wang, d Wei 2011).  Sparstolonin B, a 
bioactive compound isolated from S. stoloniferum,  has already been shown to act as a 
potent anti-inflammatory agent.  In experiments with mouse and human macrophages, 
SsnB inhibited Toll-like receptor (TLR) 2 and 4 mediated inflammation, decreasing 
cytokine release.  SsnB crosses the cell membrane and inhibits the TLRs by blocking 
MyD88 recruitment, an important step in TLR signalig.  SsnB belongs to the polyphenol 
family of compounds; its structure is similar to iscoumarin and xanthone, both strong 
anti-inflammatory compounds (Liang et al. 2011).  
 We have demonstrated the potential of Sparstolonin B as an inhibitor of 
angiogenesis.  SsnB inhibited angiogenesis-related cell activities in functional assays in 
vitro, altered the expression of angiogenesis related genes, and inhibited ex vivo 
angiogenesis.  The first part of the project showed that SsnB inhibited angiogenic 
activities of endothelial cells in functional assay, including the Matrigel tube formation 
assay and the Transwell cell migration assay.  In the second part of the project, we 
utilized microarrays and qRT-PCR to demonstrate that SsnB altered the expression of 
genes in HUVECs and HCAECs related to cell cycle progression, cytokinesis, nuclear 
division, cytoskeleton, and chemotaxis, all important pathways in angiogenesis.  We were 
especially interested in the downregulation of the cell cycle proteins CCNE2 and CDC6, 
which control progression through the G1/S checkpoint.  Using flow cytometry, we 
demonstrated that SsnB blocked cell cycle progression at this checkpoint.  In the third 
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part of the project, we showed that SsnB blocked ex vivo angiogenesis in the chick 
chorioallantoic membrane assay.  Overall, SsnB may prove to be a successful alternative 
therapy for angiogenesis-related disorders, including cancer, rheumatoid arthritis, and 
atherosclerosis.  
SsnB inhbits angiogenic functions in endothelial cells 
 In the first part of the project, we demonstrated that SsnB inhibits endothelial cell 
activity in several functional assays.  SsnB caused a dose-dependent reduction of total 
tube length in the Matrigel tube formation assay with HUVECs, HCAECs, and 
HMVECs.  Increasing the concentration of SsnB from 1 to 100 micromolar increased the 
level of inhibition compared to the vehicle control.  In all the SsnB treatment groups, the 
endothelial cells showed morphological changes, including cell rounding and clumping.  
We initially believed that this might be a sign of cell death or apoptosis induced by SsnB.  
However, a live/dead assay showed that SsnB had no effect on cell viability.  In all SsnB 
treatment groups, we observed no cell death; all cells stained positively for viable cells.  
We hypothesize that SsnB is affecting pathways related to cell morphology and motility.  
Anti-angiogenic agents often inhibit cell motility b  targeting the actin cytoskeleton and 
microtubule system (Karna et al. 2012).  SsnB may be acting in this manner, preventing 
the necessary changes in cell shape and movement necessary for tube formation in the 
Matrigel assay.  This would also explain the changes in morphology and cell clumping 
seen in our Matrigel assays.  
 In addition, SsnB treatment resulted in a dose-dependent inhibition of endothelial 
cell migration in the Transwell insert assay.  HUVECs and HCAECs experienced a dose-
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dependent inhibition in migration in response to SsnB concentrations from 0.0001 and 
0.1 µM that reached a plateau between 0.1 and 100 µM of SsnB.  The cell migration 
assay relied upon VEGF-directed chemotaxis.  Therefore, SsnB must somehow interfere 
with chemotaxis, through mechanisms which could range from inhibition of VEGF 
signaling to impaired cell motility or adhesion.  Our microarray datasets demonstrated an 
enrichment in genes associated with chemotaxis, cytoskeleton, and cell adhesion, which 
may provide clues as to how SsnB inhibits cell migration.  Perhaps SsnB is causing 
endothelial cells to adopt an adhesive state, limiting chemotaxis.  Compared to the 
Matrigel tube formation assay, the cell migration assay demonstrated a dose-dependent 
inhibition at lower concentrations of SsnB (between 0.0001 and 0.1 µM), which reached 
a plateau at 0.1 µM.  This may indicate that cell migration is more sen itive to SsnB 
exposure compared to tube formation. 
 The inhibition in tube formation and cell migration by SsnB may involve 
targeting the cell motility apparatus through altera ions in the actin cytoskeleton and 
microtubule system.  The cytoskeleton is the main driving force for cell movement and 
shape change.  Actin is the key component of the cytoskeleton, which controls cell 
locomotion.  Cellular movement involves a coordinated effort of actin polymerization 
and depolymerization, as well as focal adhesion assembly and disassembly.  
Microtubules interact with the actin cytoskeleton, provide structural support, and play a 
key role in establishing cell polarity and centrosome orientation.  These processes help 
establish a leading edge in the cell that is utilized for directed movement.  Intermediate 
filaments, including vimentin, are important components of the cytoskeleton, providing 
cell shape and participating in interactions between actin filaments and microtubules.   
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Stress fibers and focal adhesions are additional structures associated with the 
cytoskeleton that play a strong role in cell movement and migration.  Stress fibers 
represent organized centers of actin filaments, myosin, and intermediate filaments that 
generate force for cell movement, migration, and adhesion.  Focal adhesions are complex 
protein structures through which the cytoskeleton interacts with the extracellular matrix, 
establishing attachment points with the ECM as cell movement occurs.  Cell movement is 
comprised of three distinct phases (protrusion, attachment, and traction) that all 
incorporate interactions between microfilaments, microtubules, stress fibers, and focal 
adhesions.  Cell motility begins with the protrusion of lamellopodia from the leading 
edge of the cell, mainly through actin polymerization.  As the lamellopodia extend across 
the underlying surface, the cell attaches and detach s to ECM components through 
specialized receptors, including integrins.  During traction, the bulk of the cell is carried 
forward toward the leading edge.  Overall, any disruptions in the cytoskeleton or 
associated structures lead to inhibition of cell mobility (Fenteany and Zhu 2003; 
Lamalice, Le Boeuf, and Huot 2007; Mackay 2008). 
 Some naturally derived compounds target the actin cytoskeleton or microtubules 
to inhibit cytoskeleton dependent functions, including cell migration.  They may inhibit 
actin / microtubule polymerization leading to cytoskeleton destabilization, or promote 
actin / microtubule polymerization leading to cytoskeleton stabilization.  In both cases, 
cell motility becomes limited due to disruption in normal cytoskeleton functioning, 
ultimately inhibiting processes, such as angiogenesis, that depend on cell movement.  
Cytochalasins, a group of fungally derived molecules, bind the barbed ends of 
microfilaments and block polymerization and depolymerization, effectively capping the 
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growing end and preventing extension of actin filaments into the leading edge of the cell.  
Phalloidin, another fungally derived compound, stabilizes actin filaments, promotes actin 
polymerization, and inhibits depolymerization, locking actin filaments in place (Fenteany 
and Zhu 2003).  Compounds that target microtubules include taxanes and epothilones, 
which inhibit tubulin depolymerization and promote microtubule stabilization, and vinca 
alkaloids that inhibit polymerization and mitotic spindle formation (Bijman et al. 2006).    
In addition, compounds may also target upstream signaling pathways that control 
microfilaments and microtubules.  Intracellular targets for microfilament and microtubule 
disruption include Rho GTPases, a family of signaling molecules that control cell 
motility.  Tumor-derived VEGF has been shown to activ te Rho GTPases, including 
Cdc42, Rac1, and RhoA.  Once activated, these signalin  molecules affect cytoskeletal 
organization, including filopodia, lamellipodia, and stress fibers, all impacting cell shape 
and motility.  Furthermore, cdc42 affects the orientation of the centrosome and cell 
polarity, RhoA controls actin-myosin contraction promoting cell movement, and Rac1 
promotes actin polymerization in the leading edge and focal adhesion formation.  
Inhibition of these signaling molecules leads to disruptions in the cytoskeleton, stress 
fiber formation, and focal adhesion.  Many of these inhibitory compounds possess 
polycyclic structures and functional groups similar to SsnB (Vincent et al. 2001; 
Fenteany and Zhu 2003; Karna et al. 2012).  Based on the results from the cell migration 
and tube formation experiments, as well as the microarray data described below, we 
believe that SsnB may act in part by targeting the cytoskeleton or upstream signaling 




SsnB alters endothelial gene expression and limits cell cycle progression 
 We also demonstrated that SsnB altered the expression of genes implicated in 
angiogenesis.  Microarray data from human umbilical vein endothelial cells and human 
coronary artery endothelial cells showed altered expr ssion in genes associated with a 
variety of biological processes, including cell divis on, cell cycle progression, 
chemotaxis, and cytoskeleton, which may provide insight into the results seen in the tube 
formation and cell migration experiments.  The majority of the enriched genes are also 
associated with mitosis.  Many genes that are usually pregulated during progression 
through the cell cycle to mitosis were downregulated in our microarray data, including 
genes such as anillin (ANLN), cyclin E2 (CCNE2), cell division cycle 6 (CDC6), cyclin 
B1 (CCNB1), cyclin dependent kinase 1 (CDC2), and aurora kinases A and B (AURKA, 
AURKB) (Dephoure et al. 2008).  Clearly, SsnB has shown a strong effect on mitosis and 
the events preceding mitosis.  Downregulation of these genes may hinder the necessary 
cell division and proliferation that is required for angiogenesis.  Based on our cell cycle 
experiments, we believe that SsnB is causing blockage at two checkpoints in the cell 
cycle, the G1/S and G2/M checkpoints, with the former checkpoint dominating.  Overall, 
the microarray data supported the results of our functional assays and provided insight 
into the mechanism of inhibitory action through pathways including cell cycle 
progression, cytoskeleton alterations, and chemotaxis.  
 The genes from the microarray data that initially captured our attention were those 
involved in the cell cycle.  Table 2.1 demonstrates that CCNE2, CDC6, CCNB1, and 
CDC2 were all downregulated by SsnB.  Cyclins are regulatory proteins that bind and 
activate cell dependent kinases, most importantly cyclin dependent kinase 2 (CDK2), 
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which phosphorylate additional proteins, initiating a cascade of cellular events that 
prepare the cell for mitosis and division.  Cyclin levels rise and fall depending on the 
phase of the cell cycle.  Normally, CCNE2 and CCNB1 rise in the G1/S and G2/M 
phases, respectively.  CCNE2 binds and activates CDK2, which phosphorylates 
retinoblastoma protein, allowing it to dissociate from the E2F transcription factor.  E2F is 
then free to activate gene transcription and promote progression through the G1/S 
checkpoint.  CDC6 plays an essential role in chromosome duplication during the S phase.  
CCNB1 binds and activates CDC2 during progression through the G2/M checkpoint, 
preparing the cell for mitosis (Wu et al. 2009; Borlado and Mendez 2008).  The 
downregulation of CCNE2 and CDC6 directly supports the G1/S blockage observed in 
our cell cycle experiments with synchronized endothelial cells.  We believe that SsnB is 
downregulating CCNE2 and CDC6, slowing progression through the G1/S checkpoint.  
The microarray data also showed a downregulation of CCNB1 and CDC2, which should 
trap cells at the G2/M checkpoint and prevent endothelial cells from entering the final 
stages of cell division.  This effect was less readily seen due to blockage at the G1/S 
checkpoint.  In non-synchronized (no serum starvation) HUVECs, G2/M blockage was 
observed (see Appendix, Figure A.5) but at much lower levels compared to the G1/S 
blockage. 
 In addition to the cell cycle regulatory genes, there were additional genes 
associated with mitosis and the cytoskeleton that stood out in our microarray data.  The 
microarray data showed an enrichment in genes encoding proteins associated with the 
spindle, nuclear envelope, chromosome condensation nd segregation, and cytokinesis, 
all important aspects of mitosis and cell division.  SsnB caused a downregulation in the 
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expression of anillin (ANLN), an actin binding protein that plays an important role in 
cytokinesis, the final stage of cell division.  This could inhibit contractile ring formation, 
preventing the cytoskeletal changes necessary for cyt kinesis (Piekny and Maddox 
2010).  Decreased expression of anillin might explain the nuclei clumping or double 
nuclei that we observed in additional experiments (see Appendix Figure A.6) with 
nuclear staining (Hoechst).  Our microarray data also contained many examples of 
differentially downregulated cytoskeleton- related genes, including transforming acidic 
coiled-coil containing protein 3 (TACC3), hyaluronan-mediated motility receptor 
(HMMR), and diaphanous homolog 3 (DIAPH3).  Downregulation of the protein 
products of these genes may have a negative influence o  cytoskeleton functioning, 
which is essential for not only mitosis and cytokinesis, but for cell motility as well.  
DIAPH3 is an essential element in filopodia and lamellopodia formation, both important 
processes for cell motility.  Downregulation of DIAPH3 may inhibit lamellopodia / 
filopodia protrusion and subsequent cell spreading (Yang et al. 2007).  This may explain 
the cell rounding that we noticed in the tube formation experiments.  TACC3 mainly 
controls microtubules and is intricately involved with the centrosome and mitotic spindle 
apparatus during mitosis.  The spindle apparatus is required for separation of sister 
chromatids and subsequent nuclear division.  Any disruption of this process could 
negatively affect cell proliferation.  Furthermore, aurora kinases (AURKA and AURKB), 
which were also downregulated in our data, help regulate TACC3-mediated formation of 
the mitotic spindle apparatus (Piekorz et al. 2002; Kinoshita et al. 2005).  Hyaluronan-
mediated motility receptor (HMMR or RHAMM) is a protein that regulates microtubule 
function during mitosis and the turnover of focal adhesions.  RHAMM has been shown to 
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be important for endothelial cell migration during angiogenesis.  Antibodies directed 
against RHAMM effectively inhibited angiogenesis asociated with cancer (Yang et al. 
2010).  RHAMM was also downregulated in our microaray data, suggesting its 
involvement in the inhibition of endothelial cell migration and angiogenesis seen in our 
experiments. 
 Kinesin family member 18A (KIF18A) is another gene that was downregulated in 
our microarray data.  Its functions encompass a variety of pathways, including the 
cytoskeleton, cell cycle progression, and cell division, which are all the main mechanistic 
processes that we believe SsnB targets to inhibit angiogenesis.  KIF18A is a molecular 
motor that produces force and movement along microtubules to aid in cytoskeleton re-
arrangement, especially chromosome movement.  KIF18A has also been shown to 
interact with caveolin-1 (CAV1) (Luboshits and Benayahu 2005, 2007).  Caveolin-1 is 
involved in cellular pathways associated with cell morphology and stress fiber formation.  
Silencing of caveolin-1 has been shown to inhibit angiogenesis through multiple 
mechanisms including alterations in cell morphology (increased cell size and stress fiber 
formation) and inhibition in cell migration and progression through the G1/S checkpoint.  
These findings connect especially well with our results since we demonstrated a similar 
behavior in endothelial cells in response to SsnB treatment.  We hypothesize that SsnB 
may inhibit caveolin-1-mediated activities through downregulation of KIF18A.  
Caveolin-1 also signals through the AKT pathway; SsnB may somehow interfere with 
this signaling pathway (Madaro et al. 2013).  Prior esearch has shown that SsnB inhibits 
NF-κB, ERK, JNK, and p38 pathways in macrophages.  Inhibition of the AKT pathway 
may be another mechanism to inhibit caveolin-1-mediat  signaling.  Further research is 
 
64 
necessary to test this hypothesis.  Overall, the combined effects of inhibiting cell cycle 
progression, cytokinesis, mitosis, and cytoskeletal function help explain the cytostatic 
and anti-angiogenic properties of SsnB. 
SsnB inhibits ex vivo angiogenesis 
 In the final portion of the research project, we utilized the chick chorioallantoic 
membrane assay to examine the effects of SsnB on ex vivo angiogenesis.  
Methylcellulose discs containing either 100 µM SsnB or vehicle control (0.1% DMSO) 
were added to the CAM of chicken eggs.  After incubation for two days, the blood vessel 
length and branching pattern were examined.  SsnB caused a significant reduction in total 
blood vessel length compared to the vehicle control gr up, successfully demonstrating 
the ability of SsnB to inhibit ex vivo angiogenesis.   We also demonstrated that SsnB 
reduced the number of branch points in developing blood vessels.  
 The CAM assay incorporates multiple cell types, unlike in vitro functional assays.  
In vitro assays, including the Matrigel tube formation assay, only examine the effects of a 
test compound on one isolated cell type, namely endothelial cells.  Oftentimes, a 
compound that exhibits anti-angiogenic properties with in vitro functional assays may not 
inhibit in vivo or ex vivo angiogenesis.  Furthermore, compounds such as SsnB may 
inhibit angiogenesis by targeting additional cell types, and this type of interaction can be 
revealed by in vivo / ex vivo assays.  Angiogenesis is a multicellular process involving 
multiple cell types including endothelial cells and supporting cells, such as pericytes, 
smooth muscle cells, myofibroblasts, and macrophages.  For example, pericytes and 
myofibroblasts help produce collagen fibers to create a framework for vessel formation 
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during splitting or intussusceptive angiogenesis, and macrophages produce matrix 
metalloproteinases that degrade the basement membrane, providing a path for cell 
migration.   Normal angiogenesis also involves cellinteractions with the extracellular 
matrix, which are not properly addressed by in vitro assays.  Moreover, cultured 
endothelial cells have been preselected by passaging to adopt a proliferative phenotype, 
which is uncharacteristic of in vivo angiogenesis.  The CAM assay includes multiple cell 
types and extracellular matrix interactions to address all of these issues associated with in 
vitro assays (Ribatti 2008; Cimpean, Ribatti, and Raica 2008).  Using the CAM assay, we 
demonstrated that SsnB effectively inhibited angiogenesis, by decreasing total blood 
vessel length and by reducing branch number.  This data demonstrates that SsnB is 
capable of inhibiting true, physiological angiogenesis.      
 Interestingly, SsnB caused a significant reduction in the number of branches in 
the developing CAM blood vessels.  Blood vessel branch points have been shown to 
colocalize with macrophages that secrete matrix metalloproteinases (MMP) which are 
necessary for establishing these branch points.  MMPs, especially MMP-9, help degrade 
the extracellular matrix, providing access routes for endothelial cells to migrate through 
the ECM to create new branches from the original blood vessels as angiogenesis 
progresses (Johnson et al. 2004).  The observed decrease in CAM vessel branching may 
reflect an inhibitory action on macrophages by SsnB.  Previous research has shown that 
SsnB is capable of inhibiting macrophage-mediated inflammation by blocking toll-like 
receptor signaling.  In addition to its effects on endothelial cells, SsnB may also be 
inhibiting macrophage production of MMPs or other proteolytic enzymes, thereby 
reducing the density of branching usually seen in angiogenesis in the CAM assay. 
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Limitations and Future Work 
 Although our research has yielded promising results in demonstrating the anti-
angiogenic potential of SsnB, our results are still constrained by limitations associated 
with our experimental models.  Initial experiments with SsnB only utilized in vitro assays 
to investigate endothelial cells, leaving out supporting cells involved in angiogenesis, 
including macrophages, pericytes, and smooth muscle cells.  Our in vitro assays also only 
investigated three functional aspects of angiogenesis:  chemotaxis, tube formation, and 
cell cycle progression.  Since our microarray data contained such a large number of 
differentially regulated genes associated with the cytoskeleton, it would be beneficial to 
investigate how SsnB alters the cytoskeleton and how t is impacts chemoattractant 
driven angiogenesis.  We could begin by studying how SsnB alters stress fiber formation 
and cell shape through phalloidin staining.  This would be helpful in examining the cell 
shape changes that were seen in the tube formation experiment.  We may also study how 
SsnB affects focal adhesion formation with staining for integrins or associated proteins, 
such as vinculin (Wickstrom, Alitalo, and Keski-Oja 2004).  This would begin to address 
the question of whether SsnB is impeding cell migrat on by causing the endothelial cells 
to adopt an adhesive phenotype.  Both of the preceding experiments may be utilized 
concurrently with a scratch wound healing assay to further investigate the effects on 
chemotaxis.  In addition, assays with multiple celltypes, including supporting smooth 
muscle cells or pericytes, may be utilized to examine the impact of SsnB on additional 
cell types (Suboj et al. 2012).  We may also examine how SsnB affects macrophages in 
relation to angiogenesis, including metalloproteinase production.  This would expand 
upon the results that we saw in the CAM assay in regards to branching inhibition. 
 
67 
 We utilized the CAM assay as an ex vivo assay to investigate the effects of SsnB 
in a multicellular environment, incorporating interactions with the ECM.  However, the 
CAM assay also has associated limitations.  The CAM assay is not a mammalian assay; 
differences exist between chicken cells and mammalian cells.  Since chick embryos do 
not have a mature immune system until the late stage  of incubation, specific interactions 
between SsnB and lymphoid cells, such as T and B lymphocytes, cannot be examined.  
Furthermore, nonspecific inflammatory reactions to the methylcellulose discs may occur 
as activated macrophages release inflammatory cytokines in response to added 
compounds.  In addition, the CAM is undergoing consta t morphological changes, 
including contraction, that may alter the vascular density independent of the tested 
compound (Ribatti 2008).  The ex ovo version of the CAM assay employed in this project 
also exhibited a high mortality rate in embryo survival.  The Matrigel plug assay may be 
used to overcome these problems and to provide additional support for our findings from 
the CAM assay.  The Matrigel plug assay is widely used to study in vivo angiogenesis.  
The assay is simple, reproducible, and reveals more important information than in vitro 
assays, such as the Matrigel tube formation assay.  In this assay, Matrigel is injected 
subcutaneously in mice.  Over time, endothelial cells from each host mouse invade the 
Matrigel plugs, producing capillary networks.  Drug delivery pumps may be 
subcutaneously implanted in the mice during this period to study how test compounds 
affect angiogenesis.  After enough time has progressed for capillary formation to occur 
within the Matrigel, the mice are injected intravenously with Dextran-FITC to allow 
visualization and quantification of vessel formation.  After removing the plugs, the gross 
vessel distribution is noted with a fluorescent dissecting scope, and fluorescent images 
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are collected and analyzed (Staton, Reed, and Brown 2009).  SsnB is expected to 
decrease the number of capillaries that grow into the Matrigel plugs as it has shown the 
ability to inhibit angiogenesis for in vitro models and the CAM model.  Furthermore, this 
assay could provide additional insight into the effects of SsnB on capillary structure and 
cell composition.  This will provide a more complete picture of how SsnB affects 
multiple mammalian cell types, including immune cells. 
 The Matrigel plug assay only stimulates the growth of capillaries.  The hindlimb 
ischemia model may be used as an in vivo assay for angiogenesis and arteriogenesis.  In 
this model, the femoral artery in the hindlimb of the mouse is ligated to provide an area 
of ischemia that will stimulate blood vessel formation and remodeling.  Decreased 
bloodflow in the hindlimb is monitored with Doppler ultrasound.  This model stimulates 
growth of both capillaries and larger caliber vessels, compared to the Matrigel plug assay 
which only stimulates angiogenesis (van Royen et al. 2001).  In our CAM assay, we only 
studied the effects of 100 µM SsnB on angiogenesis due to the limited number of 
embryos that remained viable over the course of the exp riment.  It would be more ideal 
to study the effects of several concentrations of SsnB for a dose-response study.  This 
may be accomplished with the Matrigel or hindlimb ischemia assays.  For the CAM 
assay, we based our concentration (100 µM) on results from the in vitro experiments.  We 
may need to carry out a series of preliminary experim nts to test the feasibility of 
different delivery methods (osmotic mini pumps or int aperitoneal injections) for SsnB.  
These experiments may provide us with more insight into the effective dose ranges of 
SsnB for different in vivo models. 
 
69 
 Before beginning additional in vivo experiments, it would be especially helpful to 
determine the pharmacokinetics of SsnB.  We need to know more about how SsnB is 
absorbed through various routes of administration, and which route works best.  Using a 
murine model, we should investigate how SsnB becomes distributed within the body over 
time.  This would show us in which tissues SsnB becomes enriched, providing clues into 
the bioavailability of SsnB.  Furthermore, it would also be interesting to investigate how 
the body eliminates SsnB through metabolism and excretion.  This could demonstrate 
potential toxic byproducts from metabolic degradation of SsnB.  To begin the 
pharmacokinetic studies, we need to have a method to detect SsnB in plasma and urine 
samples.  SsnB could be conjugated with markers for detection in these assays, or 
antibodies directed against structural motifs of SsnB could be created for ELISAs or 
western blots.  Overall, SsnB has proven effective in inhibiting angiogenesis in our 
experiments, but its efficacy could be improved.  SsnB may serve as a starting point for 
derivatized compounds.  Functional groups may be add d or modified to improve the 
solubility, bioavailability, and activity of SsnB.  These derivatized compounds may also 
possess additional therapeutic properties (Liang et al. 1995). 
 In addition, we could learn more about the mechanism of action for SsnB by 
investigating potential binding sites.   An understanding of the initial steps of SsnB 
binding to endothelial cells will reveal additional details about downstream pathways, 
confirming our prior microarray data.  The Aryl Hydrocarbon Receptor (AHR) seems a 
likely candidate due to the polycyclic structure of SsnB and the connection between the 
AHR pathway and inhibition of HIF-1α -driven angiogenesis.  The upregulation of AHR-
associated genes, NQO1, ALDH3A1, CYP1A1, and CYP1B1, in our preliminary 
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microarray data also provides supporting evidence for the Aryl Hydrocarbon Receptor as 
a binding site for SsnB.  The aryl hydrocarbon receptor binds polycyclic and halogenated 
aromatic hydrocarbons.  After AHR binding, the AHR ligand complex and the AHR 
nuclear translocator (ARNT), also known as hypoxia-inducible factor-1β (HIF-1β), form 
a heterodimeric transcription factor.  This complex binds to xenobiotic response elements 
in the promoter region of target genes.  Hypoxia-inducible factor-1α (HIF-1α) is another 
basic helix-loop-helix transcription factor that dimerizes with ARNT and mediates VEGF 
gene activation during hypoxic conditions.  Recent r search has suggested a link between 
AHR-ARNT signaling and the regulation of angiogenesis.  The AHR and HIF-1 α both 
compete for the ARNT; therefore, increased activation of AHR can decrease hypoxia- 
driven angiogenesis.  SsnB possesses a polycyclic structure, making it a potential ligand 
for the AHR, which may operate through AHR-ARNT signaling to inhibit angiogenesis 
(Dong, Ma, and Whitlock 1996; Forsythe et al. 1996; Ichihara et al. 2007; Reyes, Reisz-
Porszasz, and Hankinson 1992; Schmidt and Bradfield 1996; Wiesener et al. 1998). 
Conclusion 
 In conclusion, Sparstolonin B has shown promise as an effective inhibitor of 
angiogenesis.  We demonstrated that SsnB inhibited angiogenic functions in several 
functional assays, including tube formation and cell migration.  Microarray analysis 
showed that SsnB caused differential regulation of genes associated with the cell cycle, 
cell division, and cytoskeleton.  We also showed that SsnB hampered progression 
through the cell cycle at the G1/S checkpoint, possibly by downregulation of CCNE2 and 
CDC6.  SsnB successfully inhibited angiogenesis in the CAM assay, decreasing vessel 
length and branching.  Future work with SsnB will reveal more about its mechanism of 
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action, including cytoskeletal changes and possible binding sites.  Overall, SsnB has 
proven to be a powerful bioactive compound with a multitude of useful therapeutic 
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APPENDIX A –SUPPLEMENTARY DATA  
Table A.1  Gene function enrichment analysis for HUVECs in response to SsnB 
treatment 
***Gene Ontology*** 
C1 C2 C3 C4 P-value Term Name 
118 759 1470 15432 0 adenyl nucleotide binding 
114 759 1386 15432 0 ATP binding 
203 759 3326 15432 0.000397 cell communication 
123 759 772 15432 0 cell cycle 
15 759 75 15432 0.000007 cell cycle arrest 
13 759 48 15432 0.000001 cell cycle checkpoint 
64 759 258 15432 0 cell cycle phase 
107 759 653 15432 0 cell cycle process 
49 759 199 15432 0 cell division 
54 759 588 15432 0.000013 cell proliferation 
576 759 10922 15432 0.000936 cellular process 
16 759 130 15432 0.000926 chemotaxis 
38 759 286 15432 0 chromosomal part 
44 759 337 15432 0 chromosome 
13 759 43 15432 0 chromosome segregation 
16 759 48 15432 0 chromosome, pericentric region 
46 759 543 15432 0.000335 cytoskeletal part 
66 759 897 15432 0.000881 cytoskeleton 
47 759 439 15432 0.000001 cytoskeleton organization and biogenesis 
17 759 119 15432 0.000121 cytoskeleton-dependent intracellular transport 
57 759 711 15432 0.000271 DNA metabolic process 
25 759 244 15432 0.000614 DNA repair 
29 759 189 15432 0 DNA replication 
16 759 96 15432 0.000033 DNA-dependent DNA replication 
15 759 67 15432 0.000002 interphase 
14 759 63 15432 0.000005 interphase of mitotic cell cyc e 
107 759 1541 15432 0.000199 intracellular non-membrane-bound organelle 
66 759 897 15432 0.000881 kinase activity 
57 759 214 15432 0 M phase 
50 759 168 15432 0 M phase of mitotic cell cycle 
25 759 202 15432 0.000037 microtubule 
16 759 113 15432 0.000209 microtubule associated complex 
37 759 290 15432 0 microtubule cytoskeleton 
 
80 
15 759 63 15432 0.000001 microtubule cytoskeleton organization and 
biogenesis 
14 759 83 15432 0.000089 microtubule motor activity 
17 759 105 15432 0.000027 microtubule-based movement 
31 759 186 15432 0 microtubule-based process 
48 759 166 15432 0 mitosis 
58 759 226 15432 0 mitotic cell cycle 
19 759 156 15432 0.000367 motor activity 
75 759 873 15432 0.000003 negative regulation of biolog cal process 
71 759 806 15432 0.000002 negative regulation of cellular process 
24 759 185 15432 0.000025 negative regulation of prgression through cell cycle 
107 759 1541 15432 0.000199 non-membrane-bound organelle 
140 759 2090 15432 0.000093 nucleotide binding 
14 759 91 15432 0.000225 phosphoinositide-mediated signaling 
319 759 5058 15432 0 protein binding 
134 759 1797 15432 0.000001 purine nucleotide binding 
8 759 37 15432 0.000589 Ras GTPase activator activity 
74 759 493 15432 0 regulation of cell cycle 
217 759 3609 15432 0.000529 regulation of cellular process 
9 759 41 15432 0.000245 regulation of cyclin-dependent protein kinase activity 
14 759 46 15432 0 regulation of mitosis 
74 759 490 15432 0 regulation of progression through cell cycle 
31 759 282 15432 0.000042 response to DNA damage stimulus 
31 759 304 15432 0.000157 response to endogenous stimulus 
47 759 492 15432 0.000018 response to external stimulus 
130 759 1996 15432 0.000545 response to stimulus 
80 759 842 15432 0 response to stress 
14 759 43 15432 0 spindle 
16 759 130 15432 0.000926 taxis 
76 759 1037 15432 0.000404 transferase activity, transferring phosphorus-
containing groups 
***Protein Domain*** 
C1 C2 C3 C4 P-value Term Name 
4 542 9 12147 0.000781 AIG1 family // 9.1E-85 
6 542 16 12147 0.000098 Cyclin, C-terminal // 4.0E-41 
12 542 41 12147 0.000001 Kinesin, motor region // 4.1E-121 
***Pathway*** 
C1 C2 C3 C4 P-value Term Name 
31 180 112 2918 0 Cell_cycle_KEGG // GenMAPP 
21 180 69 2918 0 DNA_replication_Reactome // GenMAPP 
19 180 90 2918 0.000004 G1_to_S_cell_cycle_Reactome // G nMAPP 
25 180 195 2918 0.000429 Smooth_muscle_contraction // GenMAPP 
 
C1: number of genes in a cluster or list that have this annotation term 
C2: number of annotated genes in this cluster or list  
C3: number of all genes on array that have this annotation term  
C4: number of all annotated genes on array  
P-value: binomial approximated p-value for hypergeom tric distribution  
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C1 C2 C3 C4 P-value Term Name 
56 214 1470 15432 0 adenyl nucleotide binding 
56 214 1386 15432 0 ATP binding 
15 214 360 15432 0.000177 ATPase activity 
13 214 311 15432 0.000463 ATPase activity, coupled 
87 214 4602 15432 0.000477 biopolymer metabolic proess 
93 214 5029 15432 0.000574 catalytic activity 
85 214 772 15432 0 cell cycle 
13 214 48 15432 0 cell cycle checkpoint 
51 214 258 15432 0 cell cycle phase 
71 214 653 15432 0 cell cycle process 
43 214 199 15432 0 cell division 
27 214 588 15432 0 cell proliferation 
51 214 2215 15432 0.000155 cellular component organization and biogenesis 
179 214 10922 15432 0.000009 cellular process 
32 214 286 15432 0 chromosomal part 
35 214 337 15432 0 chromosome 
19 214 377 15432 0.000002 chromosome organization and biogenesis 
15 214 363 15432 0.000194 chromosome organization and biogenesis (sensu 
Eukaryota) 
15 214 43 15432 0 chromosome segregation 
18 214 48 15432 0 chromosome, pericentric region 
6 214 34 15432 0.00001 condensed chromosome 
30 214 543 15432 0 cytoskeletal part 
31 214 897 15432 0.000003 cytoskeleton 
28 214 439 15432 0 cytoskeleton organization and biogenesis 
13 214 119 15432 0 cytoskeleton-dependent intracellular transport 
4 214 30 15432 0.000877 DNA damage response, signal transduction 
45 214 711 15432 0 DNA metabolic process 
21 214 244 15432 0 DNA repair 
30 214 189 15432 0 DNA replication 
9 214 42 15432 0 DNA-dependent ATPase activity 
18 214 96 15432 0 DNA-dependent DNA replication 
4 214 26 15432 0.000517 double-stranded DNA binding 
21 214 618 15432 0.000162 hydrolase activity, acting o  acid anhydrides 
21 214 615 15432 0.000152 hydrolase activity, acting o  acid anhydrides, in 
phosphorus-containing anhydrides 
12 214 67 15432 0 interphase 
12 214 63 15432 0 interphase of mitotic cell cycle 
140 214 7906 15432 0.000019 intracellular 
108 214 5631 15432 0.000021 intracellular membrane-bound organelle 
60 214 1541 15432 0 intracellular non-membrane-bound organelle 
122 214 6494 15432 0.000008 intracellular organelle 
 
82 
62 214 2068 15432 0 intracellular organelle part 
131 214 7364 15432 0.00005 intracellular part 
47 214 214 15432 0 M phase 
45 214 168 15432 0 M phase of mitotic cell cycle 
108 214 5633 15432 0.000021 membrane-bound organelle 
17 214 202 15432 0 microtubule 
13 214 113 15432 0 microtubule associated complex 
28 214 290 15432 0 microtubule cytoskeleton 
12 214 63 15432 0 microtubule cytoskeleton organization and 
biogenesis 
13 214 83 15432 0 microtubule motor activity 
6 214 64 15432 0.000303 microtubule organizing center 
13 214 105 15432 0 microtubule-based movement 
25 214 186 15432 0 microtubule-based process 
44 214 166 15432 0 mitosis 
50 214 226 15432 0 mitotic cell cycle 
13 214 156 15432 0 motor activity 
60 214 1541 15432 0 non-membrane-bound organelle 
21 214 583 15432 0.000073 nucleoside-triphosphatase ctivity 
56 214 2090 15432 0.000001 nucleotide binding 
101 214 3964 15432 0 nucleus 
122 214 6495 15432 0.000008 organelle 
44 214 1019 15432 0 organelle organization and biogenesis 
62 214 2068 15432 0 organelle part 
13 214 91 15432 0 phosphoinositide-mediated signaling 
33 214 1302 15432 0.000564 post-translational protein modification 
15 214 421 15432 0.000888 protein serine/threonine ki ase activity 
56 214 1797 15432 0 purine nucleotide binding 
21 214 612 15432 0.000142 pyrophosphatase activity 
43 214 493 15432 0 regulation of cell cycle 
73 214 3609 15432 0.000246 regulation of cellular process 
7 214 41 15432 0.000002 regulation of cyclin-dependent protein kinase activity 
5 214 43 15432 0.00037 regulation of DNA metabolic process 
13 214 46 15432 0 regulation of mitosis 
43 214 490 15432 0 regulation of progression through cell cycle 
24 214 282 15432 0 response to DNA damage stimulus 
24 214 304 15432 0 response to endogenous stimulus 
30 214 842 15432 0.000002 response to stress 
13 214 219 15432 0.000015 second-messenger-mediated s gnaling 
13 214 43 15432 0 spindle 
28 214 1037 15432 0.00059 transferase activity, transferring phosphorus-
containing groups 
8 214 143 15432 0.000965 ubiquitin-protein ligase activity 
***Protein Domain*** 
C1 C2 C3 C4 P-value Term Name 
5 130 47 12147 0.000166 AAA ATPase, central region // 2.2E-18 
4 130 29 12147 0.00029 BRCT // 9.8E-9 
 
83 
4 130 16 12147 0.00003 Cyclin, C-terminal // 4.0E-41 
4 130 31 12147 0.000373 Cyclin, N-terminal domain // 3.6E-14 
12 130 41 12147 0 Kinesin, motor region // 4.1E-121 
2 130 4 12147 0.000884 Lysophospholipase, catalytic domain // 2.4E-63 
2 130 3 12147 0.000501 M-phase inducer phosphatase // 1.7E-30 
6 130 10 12147 0 MCM // 2.1E-66 
2 130 4 12147 0.000884 SMC protein, N-terminal // 3.7E-50 
***Pathway*** 
C1 C2 C3 C4 P-value Term Name 
27 60 112 2918 0 Cell_cycle_KEGG // GenMAPP 
22 60 69 2918 0 DNA_replication_Reactome // GenMAPP 
16 60 90 2918 0 G1_to_S_cell_cycle_Reactome // GenMAPP 
 
C1: number of genes in a cluster or list that have this annotation term 
C2: number of annotated genes in this cluster or list  
C3: number of all genes on array that have this annotation term  
C4: number of all annotated genes on array  





Figure A.1  8-Isoprostane Staining in Sections of Carotid Arteries 
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Figure A.3  Heatmap of differentially regulated genes in HUVECs and HCAECs 
 
87 





Figure A.5  SsnB causes G2/M blockage in non-synchronized HUVECs  
 
 
Figure A.6  Representative images demonstrating double nuclei (indicated by arrows) 
 
